



**Microvesicle protein levels are related to brain atrophy and cerebral white matter lesions in patients with manifest vascular disease: the SMART-MR study**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003824
Article Type:	Research
Date Submitted by the Author:	18-Aug-2013
Complete List of Authors:	Kanhai, Danny; University Medical Center Utrecht, Vascular Medicine de Kleijn, Dominique Kappelle, Jaap; University Medical Center Utrecht, Neurology Uiterwaal, Cuno; University Medical Centre Utrecht, Epidemiology van der Graaf, Yolanda; Julius Center for Health Sciences and Primary Care Pasterkamp, Gerard; University Medical Center Utrecht, Experimental Cardiology Laboratory Geerlings, Mirjam; Julius Center for Health Sciences and Primary Care Visseren, Frank; University Medical Center Utrecht, Department of Vascular Medicine
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Neurology
Keywords:	VASCULAR MEDICINE, Ischaemic heart disease < CARDIOLOGY, EPIDEMIOLOGY, NEUROPATHOLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3 **Microvesicle protein levels are related to brain atrophy and cerebral white matter lesions**  
4 **in patients with manifest vascular disease: the SMART-MR study**  
5  
6

7  
8 Danny A. Kanhai <sup>1</sup>, Dominique P.V. de Kleijn <sup>2,3,4</sup>, L. Jaap Kappelle <sup>5</sup>, Cuno S.P.M. Uiterwaal <sup>6</sup>,  
9 Yolanda van der Graaf <sup>6</sup>, Gerard Pasterkamp <sup>2</sup>, Mirjam I. Geerlings <sup>6</sup>, Frank L.J. Visseren <sup>1</sup>  
10 on behalf of the SMART Study Group\*  
11

12  
13  
14 <sup>1</sup> Department of Vascular Medicine, University Medical Center Utrecht (UMC Utrecht),  
15 Utrecht, The Netherlands

16  
17 <sup>2</sup> Experimental Cardiology Laboratory, UMC Utrecht, Utrecht, The Netherlands

18  
19 <sup>3</sup> Interuniversity Cardiology Institute of the Netherlands (ICIN) Utrecht, the Netherlands

20  
21 <sup>4</sup> Surgery (NUS) and Cardiovascular Research Institute (NUH) Singapore

22  
23 <sup>5</sup> Department of Neurology, Utrecht Stroke Centre, Rudolf Magnus Institute of Neuroscience,  
24 UMC Utrecht, The Netherlands

25  
26 <sup>6</sup> Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht, The Netherlands

27  
28 \* Listed in acknowledgements  
29

30  
31 **Correspondence:**

32 Frank L.J. Visseren, MD, PhD; Department of Vascular Medicine, UMC Utrecht,

33 F02.126, Heidelberglaan 100; 3584 CX Utrecht, The Netherlands

34  
35 Phone: +31 88 75 555 55; Fax: +31 88 75 554 88; e-mail: [f.l.j.visseren@umcutrecht.nl](mailto:f.l.j.visseren@umcutrecht.nl)  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

### *Objectives*

Microvesicles (MVs) and their protein levels have been identified as a potential risk marker for the development of vascular disease. In the present study we assessed whether levels of 4 previously identified MV proteins (Cystatin C, Serpin G1, Serpin F2 and CD14) are associated with cerebral white matter lesions (WMLs) and brain atrophy.

### *Design*

Cohort study; cross-sectional and prospective

### *Setting*

Single center, secondary and tertiary setting

### *Participants*

1309 Patients with manifest vascular disease from the Second Manifestations of ARterial disease-Magnetic Resonance (SMART-MR) study, of which 994 had successful brain Magnetic Resonance Imaging (MRI) and MV protein level measurements

### *Outcomes*

WMLs and brain parenchymal fraction (BPF), as parameter for brain atrophy, at baseline and follow-up

### *Statistical methods*

The relation between MV protein levels and WML volume (expressed as log transformed percentage of intracranial volume) and BPF (expressed percentage of intracranial volume) on 1.5 Tesla brain MRI was assessed with multivariable linear regression modeling. Subsequently, the relation between baseline MV protein levels and progression of atrophy and WMLs was analyzed in 534 patients, in whom a follow-up MRI was obtained after 4 years.

### *Results*

MV-Cystatin C and MV-CD14 were significantly associated with larger WML volume (linear regression coefficient (95% confidence interval) 0.10 log %/SD (0.04 to 0.17) and 0.14 log %/SD (0.07 to 0.20), respectively. Higher MV-CD14 was associated with more brain atrophy (-0.14 % /SD; -0.27 to -0.01). Baseline MV-CD14 was significantly associated with increase of white matter lesions (0.11 log %/SD (0.04–0.18). No relations with MV-Serpins were observed at baseline or at follow-up.

### *Conclusions*

Microvesicle proteins Cystatin C and CD14 are related to cerebral white matter lesions and the progression of brain atrophy in patients with manifest vascular disease, potentially identifying MVs in the etiology of structural brain changes.

## Introduction

Patients with manifest vascular disease often have morphologic changes in the small vessels of the brain, characterized by white matter lesions (WML) on magnetic resonance imaging (MRI) <sup>1</sup>. The exact underlying pathophysiological mechanism regarding WMLs remains unclear. WMLs have been associated with cognitive decline <sup>2</sup> and may explain the increased risk for cognitive decline in patients with manifest vascular disease <sup>3,4</sup>. Cognitive decline and vascular disease have more in common as they share important risk factors such as obesity, hypertension, dyslipidemia and diabetes <sup>5,6</sup>.

Recently, microvesicles (MVs) have been identified as a novel, independent risk marker for the occurrence of vascular disease <sup>7,8</sup>. MVs are membrane shed vesicles, between 50 and 1000 nm in diameter, released in the extracellular space after cell activation or apoptosis, and include various phenotypes such as microparticles and exosomes <sup>9,10</sup>. MVs are defined by size and antigen expression, which depends on their originating cell type <sup>11,12</sup>. Release of MVs allows cells to influence (patho)physiological processes over distance in contrast to cell-cell contact.

MVs transfer proteins, mRNA, miRNA and bioactive lipids from one cell to another cell by either fusion or internalization with target cells <sup>13</sup>. For example, monocyte-derived MVs are internalized by endothelial cells and activate the nuclear factor- $\kappa$ B pathway and expression of adhesion molecules on these endothelial cells, amplifying inflammation <sup>14</sup>. MVs are procoagulant, as they carry phosphatidylserine on their membrane, which facilitates the assembly of components of the clotting cascade <sup>15</sup>. In addition, MVs also carry the procoagulant protein tissue factor, which is primary cellular activator of the clotting cascade <sup>16</sup>. It has been demonstrated that atherosclerotic plaques had 200-fold higher levels of MVs in comparison with plasma of the same study subjects <sup>17</sup>, suggesting an active role of MVs in atherothrombotic disease rather than a trigger of disease onset.

Virtually every cell is capable of producing MVs, including brain cells such as neurons and astrocytes <sup>18</sup>. Little is known about the role MVs play in the development of brain atrophy or small vessel disease. However, microparticles, a subclass of MVs, have been shown to influence arterial stiffness <sup>19</sup>, which is associated with cerebral small vessel disease <sup>20-22</sup>.

Alternatively, platelet derived microparticles have been suggested to play a role in the formation of cerebral microthrombi <sup>23</sup>, a known initiator of brain atrophy and subsequent cognitive decline. Exosomes, another subclass of MVs, have been shown to pass the blood-brain barrier (BBB) <sup>24,25</sup>. In a murine model a specific gene knockdown *in cerebro* was

1  
2  
3 achieved through the actions of peripherally infused modified exosomes containing specific  
4 RNA<sup>24</sup>.

5  
6 We hypothesized that MV protein levels of Cystatin C, Serpin G1, Serpin F2 and CD14, in  
7 peripherally circulating plasma MVs, which have been related to the occurrence of vascular  
8 disease previously, also are associated with the presence or increase of brain atrophy or with  
9 small vessel disease. Therefore, we investigated the relation between levels of these 4 MV  
10 proteins extracted from plasma, and brain parenchymal fraction (BPF) and white matter  
11 lesions (WMLs) in a cohort of patients with clinically manifest vascular disease.  
12  
13  
14  
15  
16  
17  
18  
19

## 20 **Methods**

### 21 *SMART-MR study*

22  
23 The study population consisted of patients participating in the Second Manifestations of  
24 ARterial disease-Magnetic Resonance (SMART-MR) study, a prospective cohort study  
25 aimed at investigating brain changes on magnetic resonance imaging (MRI) in 1,309 patients  
26 with clinically manifest vascular disease. Details of the design and participants have been  
27 described elsewhere<sup>1,26</sup>. In brief, between May 2001 and December 2005, all patients newly  
28 referred to the University Medical Center Utrecht, The Netherlands with manifest coronary  
29 artery disease (CAD), cerebrovascular disease (CVD), peripheral arterial disease (PAD), or an  
30 abdominal aortic aneurysm (AAA), and without MR contraindications, were invited to  
31 participate. CVD was defined as a recent diagnosis of ischemic stroke, transient ischemic  
32 attack or amaurosis fugax. CAD was defined as a recent diagnosis of angina pectoris,  
33 myocardial infarction or coronary revascularization (coronary artery bypass graft or coronary  
34 angioplasty). PAD consisted of those with a clinical diagnosis of Fontaine stage 2, 3 or 4.  
35 AAA was defined as an abdominal aortic aneurysm of  $\geq 3.0$  centimeter or recent aneurysm  
36 surgery.  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 Excluded were patients with a terminal disease, active malignancy, those not independent in  
47 daily activities, and those referred back to the referring specialist immediately after 1 visit.  
48 After inclusion, patients underwent a standardized vascular screening including assessment of  
49 vascular risk factors and non-invasive measurement of subclinical atherosclerosis in addition  
50 to MRI of the brain. Risk factors, medical history, and functioning were assessed with  
51 questionnaires that the patients completed prior to their visit. Of the original 1309 patients  
52 comprising this cohort, 1232 successfully underwent MRI-measurement. For 994 of these  
53 patients, material for MV protein level measurement could be retrieved and had at least one  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 MV protein level measurement. Between January 2006 and May 2009, all participants still  
4 alive (n = 1,238) were invited for follow-up measurements, including a second MRI of the  
5 brain. For 534 patients data on follow-up MRI as well as baseline MV protein levels were  
6 available. The SMART-MR study was approved by the ethics committee of the University  
7 Medical Center Utrecht, and written informed consent was obtained from all participants.  
8  
9  
10

### 11 12 13 *Magnetic resonance imaging protocol*

14 MR investigations were performed on a 1.5-Tesla whole-body system (Gyrosan ACS-NT,  
15 Philips Medical Systems, Best, The Netherlands). The protocol consisted of a transversal T1-  
16 weighted gradient-echo sequence (repetition time (TR)/echo time (TE): 235/2 ms; flip angle,  
17 80°), a transversal T2-weighted turbo spin-echo sequence (TR/TE: 2200/11 ms and  
18 2200/100 ms; turbo factor 12), a transversal T2-weighted fluid attenuating inverse recovery  
19 (FLAIR) sequence (TR/TE/inversion time (TI): 6000/100/2000 ms), and a transversal  
20 inversion recovery (IR) sequence (TR/TE/TI: 2900/22/410 ms) (field of view mm; matrix size;  
21 slice thickness, 4.0 mm; no gap; 38 slices).  
22  
23  
24  
25  
26  
27  
28

### 29 30 *Brain segmentation*

31 The T1-weighted gradient echo, IR sequence, and FLAIR sequence were used for brain  
32 segmentation with the probabilistic segmentation technique that has been described elsewhere  
33 <sup>27, 28</sup>. This segmentation program distinguishes cortical gray matter, white matter, sulcal and  
34 ventricular cerebrospinal fluid (CSF) and lesions. The results of the segmentation analysis  
35 were visually checked for the presence of infarctions and adapted if necessary to make a  
36 distinction between white matter lesions (WMLs) and infarction volumes. Total brain volume  
37 was calculated by summing the volumes of gray and white matter and, if present, the volumes  
38 of WMLs and infarcts. All volumes cranial to the foramen magnum were included. As a  
39 result, the total brain volume includes both hemispheres, brainstem, and cerebellum. Total  
40 intracranial volume (ICV) was calculated by summing the total brain volume and the volumes  
41 of the sulcal and ventricular CSF.  
42  
43  
44  
45  
46  
47  
48  
49

### 50 51 *White matter lesions*

52 Periventricular WMLs were defined as WMLs adjacent to or within one centimeter of the  
53 lateral ventricles. Deep WMLs were defined as lesions located in deep white matter tracts or  
54 without adjoined periventricular lesions. If white matter hyperintensities on T2-weighted  
55  
56  
57  
58  
59  
60

1  
2  
3 images were also hypointense on T1-weighted and FLAIR images, they were considered  
4 infarcts and therefore distinguished from WMLs.  
5  
6

### 7 8 *Brain parameters*

9  
10 Two brain parameters were used for analyses: WMLs, which was the sum of periventricular  
11 and deep WMLs in milliliters, expressed as percentage of ICV and brain parenchymal fraction  
12 (BPF), which was determined by calculating the total brain volume in milliliters as percentage  
13 of ICV. By taking percentages of ICV instead of crude brain parameters, correction for  
14 differences in head size was applied.  
15  
16  
17

### 18 19 *Microvesicle measurements*

20  
21 Complete measurement methods are described elsewhere<sup>7</sup>. MVs were isolated using  
22 ExoQuick™ (SBI) according to the manufacturer's protocol. Briefly, 150 µl EDTA plasma  
23 was centrifuged for 15 minutes at 3000 g. The supernatant was filtered over a 0.45 µm Spin-X  
24 filter (Corning), which was flushed with preheated PBS (37°C) and 38 µl ExoQuick™  
25 solution was added to the filtrate. After vortexing, the sample was stored overnight at 4°C.  
26  
27 The following day, the sample was centrifuged at 1500 g for 30 minutes at room temperature.  
28 After removing the supernatant, the pellet was lysed in 100 µl Roche Complete Lysis-M with  
29 protease inhibitors (EDTA free). Subsequently, the sample was filtered over a 0.22 µm Spin-  
30 X filter (Corning) and protein level was determined using a Pierce® BCA Protein Assay Kit  
31 (Pierce Biotechnology, Rockford, USA) before storing the sample at -80 °C. After thawing,  
32 the lysed sample was diluted 20x with Roche complete Lysis-M buffer. 50 µl of this diluted  
33 sample was analyzed in a multiplex immuno assay on levels of Cystatin C, Serpin G1, Serpin  
34 F2 & CD14, using a Bio-Rad Bioplex 200 system as described before<sup>29</sup>. Capture antibody,  
35 biotinylated detection antibody and antigen of all 4 proteins were purchased from R&D  
36 systems.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

### 48 49 *Data analyses*

50 Central estimators and their variance measures were calculated for baseline characteristics.  
51 Multivariable linear regression was performed to assess the cross sectional relationship  
52 between MV protein level in pg/ml and WMLs in % or BPF in %. The fully adjusted model  
53 included age, gender, systolic blood pressure, smoking and type 2 diabetes, as these covariates  
54 are considered to be confounding factors in the suggested relationship between microvesicle  
55 protein levels and measured structural brain changes.  
56  
57  
58  
59  
60

To fulfill linear regression assumptions, WML volumes were naturally log-transformed as they showed skewed distributions. In order to directly compare strengths of associations, linear regressions were performed per standard deviation (SD) increase in MV protein level. Secondly, we assessed the prospective relationship between baseline MV protein levels and progression in brain parameters on MRI. This was done by relating baseline MV protein levels to follow-up WML or BPF. Besides adjustment for age, gender, systolic blood pressure, smoking and type 2 diabetes, these analyses were additionally adjusted for baseline WML or BPF and follow-up time. Results are expressed as linear regression coefficients and 95% confidence intervals.

## Results

### *Baseline characteristics*

Patient characteristics are displayed in Table 1. Seventy-nine percent of the initial patients were men and the mean age was  $59\pm 10$  years. The majority of the patients had a (recent) medical history of CAD (58%), followed by CVD (26%), PAD (24%) and AAA (10%). After a mean interval time of  $3.9\pm 0.4$  years, 534 patients underwent a second MRI of the brain. This follow-up cohort comprised 80% men and a mean age of  $58\pm 9$  years. For comparisons of the two groups, we refer to supplemental Table 1.

### *Cross-sectional association between MV protein levels and WMLs or BPF*

In the fully adjusted model, MV-Cystatin C and MV-CD14 were associated with volume of WMLs. Regression coefficients per SD MV-protein were 0.10 (95%CI 0.04-0.17) for MV-Cystatin C and 0.14 (95%CI 0.07–0.20) for MV-CD14 (Table 2). Also, MV-CD14 was associated with a statistically significantly lower BPF (regression coefficient per SD MV-CD14 -0.14 (95%CI -0.27–0.01)); (Table 3). SD increases of MV-Serpin G1 and MV-Serpin F2 were not related with WMLs or BPF at baseline.

In general, adjustment for age and gender in model 2 altered the effect estimates substantially, whereas the impact that systolic blood pressure, smoking and type 2 diabetes had on the occurrence relation was relatively small. Tests for interaction by age and gender yielded non-significant results (data not shown).



1  
2  
3 *Prospective associations between MV protein levels and of WMLs or BPF*

4 In the fully adjusted model, MV-CD14 was associated with increase of WML volume  
5 (regression coefficient = 0.11 (95%CI 0.04-0.18)) as is displayed in Table 2. MV-Cystatin C,  
6 MV-Serpin G1 and MV-Serpin F2 were not related with increase of WMLs or BPF.  
7  
8  
9

10  
11  
12  
13 **Discussion**

14 In patients with various clinical manifestations of vascular disease, MV protein levels of  
15 Cystatin C and CD14 in plasma are associated with larger WMLs and more brain atrophy.  
16 Furthermore, higher MV-CD 14 levels are associated with an increase in WMLs during 4  
17 years of follow-up. This relation is independent of age, gender, systolic blood pressure,  
18 smoking and type 2 diabetes.  
19

20 The role of Cystatin C, a cysteine protease inhibitor, in the process of degenerative disorders  
21 in the brain is unclear. In vitro and murine studies have shown that Cystatin C binds to  
22 amyloid- $\beta$  ( $a\beta$ ), resulting in inhibition of  $a\beta$  deposition<sup>30-32</sup>, the characteristic component of  
23 the neuritic plaques that identify patients with Alzheimer's disease. This protective role of  
24 Cystatin C was supported in a cohort study<sup>33</sup>, where lower levels of serum Cystatin C were  
25 associated with higher risk for future Alzheimer's disease in men. However, higher levels of  
26 serum Cystatin C have also been associated with cognitive decline<sup>34,35</sup> and with WMLs<sup>36</sup> in  
27 large population-based cohort studies. In WMLs, the Cystatin C expression is upregulated in  
28 astrocytes, presumably due to a self-defense response in the process of white matter  
29 degeneration<sup>37</sup> Our results, based upon MV-Cystatin C, show similar results as increasing  
30 MV-Cystatin C is related to increased volume of WMLs. Cystatin C is secreted by all human  
31 tissues<sup>38</sup>, which presumably concomitantly shed Cystatin C<sup>+</sup> MVs in order to directly  
32 influence more distant processes.  
33  
34

35 CD14 is a cofactor for Toll-like receptor 4 (TLR4), which regulates NF $\kappa$ B expression,  
36 indicating a role for CD14 in inflammation<sup>39</sup>. CD14 is expressed on monocytes<sup>40</sup>, and it is  
37 therefore assumable that CD14<sup>+</sup> MVs originate from these monocytes. In our study, MV-  
38 CD14 levels were related to the volume and increase of WMLs. This indicates a MV-initiated  
39 inflammatory response in dealing with WMLs. These findings do not stand alone as several  
40 inflammatory biomarkers such as lipoprotein-associated phospholipase A2 (Lp-PLA2) and  
41 myeloperoxidase (MPO), have been associated with WMLs<sup>41</sup>. Although the effects of MV-  
42 CD14 on WMLs and BPF have not been assessed previously, soluble CD14 has been  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 associated with cognitive impairment and brain atrophy in patients with HIV<sup>42</sup>. Likewise,  
4 higher plasma levels of MV-CD14 were inversely related to BPF at baseline in our study.  
5 MV-Serpin G1 (C1-inhibitor) and MV-Serpin F2 ( $\alpha$ 2-antiplasmin) were not associated with  
6 WMLs or BPF in our study, suggesting no substantial role of (inhibited) fibrinolysis in the  
7 pathophysiology surrounding WMLs or brain atrophy. To our understanding this is the first  
8 report on these Serpins and their potential role in the etiology of WMLs and brain atrophy.  
9 Whether and how MVs or MV protein levels might directly influence ischemic white matter  
10 lesions or brain volume is not known. Several mechanisms are proposed. We assume that  
11 MVs have blood-brain barrier penetrating properties, based upon recent data regarding  
12 exosomes<sup>24,25</sup>. It could also be that MVs interact with endothelial cells through receptor-  
13 mediated endocytosis. Once fused with these endothelial cells, microvesicle protein levels  
14 might activate inflammation cascade signaling, leading to vascular damage and subsequent  
15 arterial stiffness. It might also activate hemostasis cascade signaling leading to the formation  
16 of (micro)thrombi. Alternatively, through endocytosis by endothelial cells, MV protein levels  
17 might influence the structural integrity of the endothelial layer resulting in greater BBB  
18 permeability. Neurodegenerative disorders as Alzheimer disease<sup>43</sup> and multiple sclerosis<sup>44</sup>  
19 have been associated with BBB integrity loss. The mechanism behind this loss is unclear and  
20 perhaps microvesicles play a role within this process. Future work will have to test these  
21 hypotheses. If true causation between MV protein levels and brain changes would be the case,  
22 strategies on influencing MV protein levels should be developed.

23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Strengths of the present prospective cohort study include the relatively large sample size with various MV protein measurements and MRIs of the brain at baseline and 3.9 years follow up, which makes reversed causality less likely. Another strength of the study is the use of automated segmentation techniques to obtain brain parameters, which provides more precise and objective estimates than visual rating scales<sup>45</sup> and enables accurate measurement of small volume changes over time<sup>46</sup>.

Potential study limitations should also be considered. First, data of only 54% of the surviving cohort was used to measure change in WML or BPF. The patients who were physically able to undergo the follow-up MRI were most likely healthier than those who did not participate, which might have led to dilution of associations. Secondly, only 4 of the numerous proteins on the surface or within MVs were measured. It could well be that besides these vascular risk markers, various other MV proteins have their etiology in the structural brain changes. Thirdly, we assume that plasma MVs which hold the proteins measured in the present study have the ability to cross the BBB in order to have their effects on the brain, influencing

1  
2  
3 WMLs and BPF. Unfortunately no data is available whether these MVs are indeed present  
4 within the brain and it would be interesting to know if these MV proteins are present in  
5 cerebrospinal fluid and have a non-cerebral origin. If these MVs can truly pass the BBB and  
6 influence pathophysiological processes in the brain, it automatically gives rise to potential  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

WMLs and BPF. Unfortunately no data is available whether these MVs are indeed present within the brain and it would be interesting to know if these MV proteins are present in cerebrospinal fluid and have a non-cerebral origin. If these MVs can truly pass the BBB and influence pathophysiological processes in the brain, it automatically gives rise to potential therapeutical purposes analogous to exosomes, as these vesicles can deliver complex drugs directly into the brain, a key step in the treatment of brain diseases or brain changes<sup>47</sup>. In conclusion, MV-Cystatin C and MV-CD14 levels are related with the volume of WMLs and with BPF on brain MRI. MV-CD14 levels are related with an increase in the total volume of WMLs during follow-up. Microvesicle proteins levels may be causally related to brain changes in patients with clinically manifest vascular disease.

### **Acknowledgments**

We gratefully acknowledge the members of the SMART study group of UMC Utrecht: P.A. Doevendans, MD, PhD, Department of Cardiology; A. Algra, MD, PhD; Y. van der Graaf, MD, PhD; D.E. Grobbee, MD, PhD, G.E.H.M. Rutten, MD, PhD, Julius Center for Health Sciences and Primary Care; L.J. Kappelle, MD, PhD, Department of Neurology; W.P.T.M. Mali, MD, PhD, Department of Radiology; F.L. Moll, MD, PhD, Department of Vascular Surgery; F.L.J. Visseren, MD, PhD, Department of Vascular Medicine.

We thank, A.H. Schoneveld, L. Collee and S. van der Weg for the measurement of the plasma microvesicle proteins.

### **Funding sources**

This work was financially supported by the UMC Utrecht Vascular Prevention Project.

### **Disclosures**

The authors declare no conflict of interest.

## References

1. Geerlings MI, Appelman AP, Vincken KL, Algra A, Witkamp TD, Mali WP, van der Graaf Y; SMART Study Group. Brain volumes and cerebrovascular lesions on MRI in patients with atherosclerotic disease. The SMART-MR study. *Atherosclerosis*. 2010; 210:130–136.
2. Breteler MM, van Swieten JC, Bots ML, Grobbee DE, Claus JJ, van den Hout JH, van Harskamp F, Tanghe HL, de Jong PT, van Gijn J, Hofman A. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. *Neurology*. 1994;44:1246-52.
3. Vinkers DJ, Stek ML, van der Mast RC, de Craen AJ, Le Cessie S, Jolles J, Westendorp RG, Gussekloo J. Generalized atherosclerosis, cognitive decline, and depressive symptoms in old age. *Neurology*. 2005;65:107-12.
4. Breteler MM, Claus JJ, Grobbee DE, Hofman A. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. *BMJ*. 1994;308:1604-8.
5. Nash DT, Fillit H. Cardiovascular disease risk factors and cognitive impairment. *Am J Cardiol*. 2006;97:1262-5.
6. Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia: how to move forward? *Neurology*. 2009;72:368-74.
7. Kanhai DA, Visseren FL, van der Graaf Y, Schoneveld AH, Catanzariti LM, Timmers L, Kappelle LJ, Uiterwaal CS, Lim SK, Sze SK, Pasterkamp G, de Kleijn DP. Microvesicleprotein levels are associated with increased risk for future vascular events and mortality in patients with clinically manifest vascular disease. *Int. J. Cardiol*. 2013. In press.
8. Sinning JM, Losch J, Walenta K, Böhm M, Nickenig G, Werner N. Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. *Eur Heart J*. 2011;32:2034-2041.
9. Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. *Trends Cell Biol*. 2009;19:43-51.

- 1  
2  
3  
4  
5 10. van der Vlist EJ, Nolte-'t Hoen EN, Stoorvogel W, Arkesteijn GJ, Wauben MH.  
6 Fluorescent labeling of nano-sized vesicles released by cells and subsequent quantitative and  
7 qualitative analysis by high-resolution flow cytometry. *Nat Protoc.* 2012;7:1311-26.  
8  
9  
10  
11 11. Jy W, Horstman LL, Jimenez JJ, Ahn YS, Biró E, Nieuwland R, Sturk A, Dignat-George  
12 F, Sabatier F, Camoin-Jau L, Sampol J, Hugel B, Zobairi F, Freyssinet JM, Nomura S, Shet  
13 AS, Key NS, Hebbel RP. Measuring circulating cell-derived microparticles. *J Thromb*  
14 *Haemost.* 2004;2:1842–1851.  
15  
16  
17  
18  
19 12. Morel O, Morel N, Hugel B, Jesel L, Vinzio S, Goichot B, Bakouboula B, Grunebaum L,  
20 Freyssinet JM, Toti F. The significance of circulating microparticles in physiology,  
21 inflammatory and thrombotic diseases. *Rev Med Interne.* 2005;26:791–801.  
22  
23  
24  
25  
26 13. Martinez MC, Tual-Chalot S, Leonetti D, Andriantsitohaina R. Microparticles: targets and  
27 tools in cardiovascular disease. *Trends Pharmacol Sci.* 2011;32:659-65.  
28  
29  
30  
31 14. Wang JG, Williams JC, Davis BK, Jacobson K, Doerschuk CM, Ting JP, Mackman N.  
32 Monocytic microparticles activate endothelial cells in an IL-1 $\beta$ -dependent manner. *Blood.*  
33 2011;118:2366-74.  
34  
35  
36  
37  
38 15. Owens AP 3rd, Mackman N. Microparticles in hemostasis and thrombosis. *Circ Res.*  
39 2011;108:1284-97.  
40  
41  
42  
43 16. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in  
44 hemostasis and thrombosis. *Arterioscler Thromb Vasc Biol.* 2007;27:1687-93.  
45  
46  
47  
48 17. Leroyer AS, Isobe H, Lesèche G, Castier Y, Wassef M, Mallat Z, Binder BR, Tedgui A,  
49 Boulanger CM. Cellular origins and thrombogenic activity of microparticles isolated from  
50 human atherosclerotic plaques. *J Am Coll Cardiol.* 2007;49:772-7.  
51  
52  
53  
54 18. Fauré J, Lachenal G, Court M, Hirrlinger J, Chatellard-Causse C, Blot B, Grange J,  
55 Schoehn G, Goldberg Y, Boyer V, Kirchhoff F, Raposo G, Garin J, Sadoul R. Exosomes are  
56 released by cultured cortical neurones. *Mol Cell Neurosci.* 2006;31:642-8.  
57  
58  
59  
60

- 1  
2  
3  
4  
5 19. Amabile N, Guérin AP, Leroyer A, Mallat Z, Nguyen C, Boddaert J, London GM, Tedgui  
6 A, Boulanger CM. Circulating endothelial microparticles are associated with vascular  
7 dysfunction in patients with end-stage renal failure. *J Am Soc Nephrol.* 2005;16:3381-8.  
8  
9  
10  
11 20. O'Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular  
12 disease in brain and kidney: cause and logic of therapy. *Hypertension.* 2005;46:200–204.  
13  
14  
15  
16 21. Ohmine T, Miwa Y, Yao H, Yuzuriha T, Takashima Y, Uchino A, Takahashi-Yanaga F,  
17 Morimoto S, Maehara Y, Sasaguri T. Association between arterial stiffness and cerebral white  
18 matter lesions in community-dwelling elderly subjects. *Hypertens Res.* 2008;31:75– 81.  
19  
20  
21  
22  
23 22. Kuo HK, Chen CY, Liu HM, Yen CJ, Chang KJ, Chang CC, Yu YH, Lin LY, Hwang JJ.  
24 Metabolic risks, white matter hyperintensities, and arterial stiffness in high-functioning  
25 healthy adults. *Int J Cardiol.* 2010;143:184–191.  
26  
27  
28  
29  
30 23. Jimenez JJ, Jy W, Mauro LM, Horstman LL, Ahn YS. Elevated endothelial microparticles  
31 in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell  
32 culture and patients with active disease. *Br J Haematol.* 2001;112:81-90.  
33  
34  
35  
36 24. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhali S, Wood MJ. Nat Biotechnol. Delivery  
37 of siRNA to the mouse brain by systemic injection of targeted exosomes. *Nat Biotechnol.*  
38 2011;29:341-5.  
39  
40  
41  
42  
43 25. Graner MW, Alzate O, Dechkovskaia AM, Keene JD, Sampson JH, Mitchell DA, Bigner  
44 DD. Proteomic and immunologic analyses of brain tumor exosomes. *FASEB J.* 2009;23:1541-  
45 57.  
46  
47  
48  
49  
50 26. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second  
51 manifestations of ARTERial disease (SMART) study: rationale and design. *Eur J Epidemiol.*  
52 1999;15:773-781.  
53  
54  
55  
56 27. Anbeek P, Vincken KL, van Osch MJ, Bisschops RH, van der Grond J. Probabilistic  
57 segmentation of white matter lesions in MR imaging. *Neuroimage.* 2004;21:1037-44.  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
28. Anbeek P, Vincken KL, van Bochove GS, van Osch MJ, van der Grond J. Probabilistic segmentation of brain tissue in MR imaging. *Neuroimage*. 2005;27:795-804.
29. Schipper HS, de Jager W, van Dijk ME, Meerding J, Zelissen PM, Adan RA, Prakken BJ, Kalkhoven E. A multiplex immunoassay for human adipokine profiling. *Clin Chem*. 2010;56:1320-8.
30. Sastre M, Calero M, Pawlik M, Mathews PM, Kumar A, Danilov V, Schmidt SD, Nixon RA, Frangione B, Levy E. Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation. *Neurobiol Aging*. 2004;25:1033-43.
31. Kaeser SA, Herzig MC, Coomaraswamy J, Kilger E, Selenica ML, Winkler DT, Staufenbiel M, Levy E, Grubb A, Jucker M. Cystatin C modulates cerebral beta-amyloidosis. *Nat Genet*. 2007;39:1437-9.
32. Mi W, Pawlik M, Sastre M, Jung SS, Radvinsky DS, Klein AM, Sommer J, Schmidt SD, Nixon RA, Mathews PM, Levy E. Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models. *Nat Genet*. 2007 ;39:1440-2.
33. Sundelöf J, Arnlöv J, Ingelsson E, Sundström J, Basu S, Zethelius B, Larsson A, Irizarry MC, Giedraitis V, Rönnekaa E, Degerman-Gunnarsson M, Hyman BT, Basun H, Kilander L, Lannfelt L. Serum cystatin C and the risk of Alzheimer disease in elderly men. *Neurology*. 2008;71:1072-9.
34. Yaffe K, Lindquist K, Shlipak MG, Simonsick E, Fried L, Rosano C, Satterfield S, Atkinson H, Windham BG, Kurella-Tamura M. Cystatin C as a marker of cognitive function in elders: findings from the health ABC study. *Ann Neurol*. 2008;63:798-802.
35. Rajagopalan P, Refsum H, Hua X, Toga AW, Jack CR Jr, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative. Mapping creatinine- and cystatin C-related white matter brain deficits in the elderly. *Neurobiol Aging*. 2012; [Epub ahead of print]

- 1  
2  
3  
4  
5  
6 36. Wada M, Nagasawa H, Kawanami T, Kurita K, Daimon M, Kubota I, Kayama T, Kato T.  
7 Cystatin C as an index of cerebral small vessel disease: results of a cross-sectional study in  
8 community-based Japanese elderly. *Eur J Neurol*. 2010;17:383-90.  
9  
10  
11  
12  
13 37. Umegae N, Nagai A, Terashima M, Watanabe T, Shimode K, Kobayashi S, Masuda J,  
14 Kim SU, Yamaguchi S. Cystatin C expression in ischemic white matter lesions. *Acta Neurol*  
15 *Scand*. 2008;118:60-7.  
16  
17  
18  
19 38. Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C. *Crit Rev Clin*  
20 *Lab Sci*. 2004;41:467-550.  
21  
22  
23  
24 39. Jiang Q, Akashi S, Miyake K, Petty HR. Lipopolysaccharide induces physical proximity  
25 between CD14 and toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-kappa B. *J*  
26 *Immunol*. 2000;165:3541-4.  
27  
28  
29  
30  
31 40. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, Leenen PJ, Liu YJ,  
32 MacPherson G, Randolph GJ, Scherberich J, Schmitz J, Shortman K, Sozzani S, Strobl H,  
33 Zembala M, Austyn JM, Lutz MB. Nomenclature of monocytes and dendritic cells in blood.  
34 *Blood*. 2010;116:e74-80.  
35  
36  
37  
38  
39 41. Wright CB, Moon Y, Paik MC, Brown TR, Rabbani L, Yoshita M, DeCarli C, Sacco R,  
40 Elkind MS. Inflammatory biomarkers of vascular risk as correlates of leukoariorosis. *Stroke*.  
41 2009;40:3466-71.  
42  
43  
44  
45  
46 42. Ryan LA, Zheng J, Brester M, Bohac D, Hahn F, Anderson J, Ratanasuwan W,  
47 Gendelman HE, Swindells S. Plasma levels of soluble CD14 and tumor necrosis factor-alpha  
48 type II receptor correlate with cognitive dysfunction during human immunodeficiency virus  
49 type 1 infection. *J Infect Dis*. 2001;184:699-706.  
50  
51  
52  
53  
54 43. Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, Vitek MP,  
55 Hovanesian V, Stopa EG. Microvascular injury and blood-brain barrier leakage in  
56 Alzheimer's disease. *Neurobiol Aging*. 2007;28:977-86.  
57  
58  
59  
60



1  
2  
3  
4  
5 44. Waubant E. Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis.  
6 *Dis Markers*. 2006;22:235-44.  
7

8  
9  
10 45. Yoshita M, Fletcher E, DeCarli C. Current concepts of analysis of cerebral white matter  
11 hyperintensities on magnetic resonance imaging. *Top Magn Reson Imaging*. 2005;16:399-  
12 407.  
13

14  
15  
16 46. van den Heuvel DM, ten Dam VH, de Craen AJ, Admiraal-Behloul F, van Es AC, Palm  
17 WM, Spilt A, Bollen EL, Blauw GJ, Launer L, Westendorp RG, van Buchem MA; PROSPER  
18 Study Group. Measuring longitudinal white matter changes: comparison of a visual rating  
19 scale with a volumetric measurement. *Am J Neuroradiol*. 2006;27:875-8.  
20  
21

22  
23  
24 47. Wood MJ, O'Loughlin AJ, Samira L. Exosomes and the blood-brain barrier: implications  
25 for neurological diseases. *Ther Deliv*. 2011;2:1095-9.  
26  
27

**Table 1: Patient characteristics**

	Baseline cohort N = 994	Follow-up patients N = 534	Non-FU patients N = 460
Age (years)*	59 ± 10	58 ± 9	60 ± 11
Male gender, n (%)	784 (79)	426 (80)	358 (78)
Body mass index (kg/m <sup>2</sup> )*	26.9 ± 3.8	26.9 ± 3.6	26.8 ± 4.1
Waist circumference (cm)*	95 ± 11	95 ± 11	96 ± 12
Blood pressure (mmHg)*			
Systolic	144 ± 22	142 ± 20	145 ± 23
Diastolic	83 ± 12	82 ± 11	83 ± 12
LDL-cholesterol (mmol/L)*	2.8 ± 0.93	2.8 ± 0.90	2.9 ± 0.97
HDL-cholesterol (mmol/L)*	1.30 ± 0.38	1.31 ± 0.38	1.28 ± 0.37
Triglycerides (mmol/L) <sup>‡</sup>	1.47 (1.09 – 2.07)	1.41 (1.05 – 2.07)	1.47 (1.09-2.07)
Glucose (mmol/L)*	6.3 ± 1.9	6.2 ± 1.8	6.4 ± 1.9
HsCRP (mmol/L) <sup>‡</sup>	1.8 (0.9 – 3.8)	1.6 (0.8 – 3.5)	1.8 (0.9 - 3.8)
eGFR (ml/min/1.73 m <sup>2</sup> )*	77.7 ± 17.9	79.7 ± 17.1	75.4 ± 18.6
Homocysteine (µmol/L)*	14.0 ± 6.0	13.5 ± 4.9	14.6 ± 7.0
Prevalent type 2 diabetes, n (%)	156 (16)	71 (13)	85 (19)
Metabolic syndrome, n (%) <sup>†</sup>	369 (37)	184 (35)	185 (40)
Smoking, n (%)			
Never	170 (17)	100 (18)	70 (15)
Ever	454 (46)	257 (48)	197 (43)
Current	370 (37)	177 (33)	193 (42)
Packyears smoking*	23.0 ± 20.5	23.0 ± 20.1	23.1 ± 21.0
History of vascular disease, n (%)			
Cerebrovascular disease	261 (26)	144 (27)	117 (25)
Coronary artery disease	580 (58)	325 (61)	255 (55)
Peripheral artery disease	241 (24)	108 (20)	133 (29)
Aneurysm of the abdominal aorta	99(10)	37 (7)	62 (14)
Medication, n (%)			
Platelet-aggregation inhibitors	740 (74)	407 (76)	333 (72)
Blood pressure-lowering agents	702 (71)	382 (72)	320 (70)
Lipid-lowering agents	682 (69)	388 (73)	294 (64)
Oral anticoagulants	80 (8)	37 (7)	43 (9)

Values are expressed as: \*Mean ± standard deviation, <sup>‡</sup>Median (interquartile range).

<sup>†</sup>Defined according to the National Cholesterol Education Program ATPIII-revised guidelines.

**Table 2: Microvesicle protein levels and white matter lesions (WML)**

	Model	WML	
		WML at baseline n=994	WML at follow-up* n= 534
MV-Cystatin C (pg/μg)	I	<b>0.27 (0.20 – 0.34)</b>	0.06 (-0.02 – 0.13)
Mean 10.6	II	<b>0.10 (0.04 – 0.17)</b>	0.01 (-0.06 – 0.08)
SD 5.3	III	<b>0.10 (0.04 – 0.17)</b>	0.01 (-0.06 – 0.08)
MV-Serpin G1 (pg/μg)	I	-0.03 (-0.10 – 0.05)	0.02 (-0.05 – 0.08)
Mean 142.2	II	-0.02 (-0.08 – 0.04)	0.02 (-0.04 – 0.08)
SD 85.6	III	-0.03 (-0.08 – 0.05)	0.03 (-0.03 – 0.09)
MV-Serpin F2 (pg/μg)	I	0.01 (-0.066 – 0.08)	-0.01 (-0.08 – 0.05)
Mean 43.3	II	0.03 (-0.034 – 0.09)	0.01 (-0.06 – 0.07)
SD 30.4	III	0.03 (-0.035 – 0.09)	0.01 (-0.05 – 0.07)
MV-CD 14 (pg/μg)	I	<b>0.23 (0.16 – 0.30)</b>	<b>0.12 (0.04 – 0.18)</b>
Mean 12.2	II	<b>0.14 (0.08 – 0.20)</b>	<b>0.10 (0.03 – 0.17)</b>
SD 3.9	III	<b>0.14 (0.07 – 0.20)</b>	<b>0.11 (0.04 – 0.18)</b>

Regression coefficients: increase in WML (log%) per 1SD increase in MV protein level (pg/ml)

Model I: Univariable model

Model II: Adjustment for age and gender

Model III: Model II with additional adjustment for systolic blood pressure, packyears smoking and prevalent type 2 diabetes mellitus

\*Models include additional adjustment for baseline WML and follow-up time

**Table 3: Microvesicle protein levels and Brain Parenchymal Fraction (BPF)**

	Model	BPF	
		BPF at baseline n=994	BPF at follow-up* n= 534
MV-Cystatin C (pg/μg)	I	<b>-0.69 (-0.86 - -0.51)</b>	<b>-0.15 (-0.26 - -0.04)</b>
<i>Mean 10.6</i>	II	-0.12 (-0.26 - 0.02)	-0.06 (-0.16 - 0.04)
<i>SD 5.3</i>	III	-0.11 (-0.24 - 0.03)	-0.05 (-0.16 - 0.05)
MV-Serpin G1 (pg/μg)	I	-0.00 (-0.18 - 0.17)	0.04 (-0.05 - 0.14)
<i>Mean 142.2</i>	II	0.01 (-0.12 - 0.14)	0.02 (-0.06 - 0.11)
<i>SD 85.6</i>	III	0.10 (-0.12 - 0.14)	0.03 (-0.06 - 0.11)
MV-Serpin F2 (pg/μg)	I	0.05 (-0.12 - 0.23)	0.06 (-0.04 - 0.16)
<i>Mean 43.3</i>	II	-0.10 (-0.23 - 0.03)	-0.01 (-0.10 - 0.08)
<i>SD 30.4</i>	III	-0.06 (-0.19 - 0.07)	0.01 (-0.09 - 0.10)
MV-CD 14 (pg/μg)	I	<b>-0.45 (-0.62 - -0.28)</b>	-0.06 (-0.17 - 0.05)
<i>Mean 12.2</i>	II	<b>-0.19 (-0.32 - -0.06)</b>	-0.05 (-0.15 - 0.05)
<i>SD 3.9</i>	III	<b>-0.14 (-0.27 - -0.01)</b>	-0.03 (-0.13 - 0.07)

Regression coefficients: increase in BPF (%) per 1SD increase in MV protein level (pg/ml)

Model I: Univariable model

Model II: Adjustment for age and gender

Model III: Model II with additional adjustment for systolic blood pressure, packyears smoking and prevalent type 2 diabetes mellitus

\*Models include additional adjustment for baseline WML and follow-up time

**Suppl. Table 1.** Baseline characteristics and mean difference between follow-up and non-follow up patients

	<b>Follow-up patients N = 534</b>	<b>Non-FU patients N = 460</b>	<b>Mean difference (95% CI)</b>
Age (years)*	58 ± 9	60 ± 11	2.4 (1.2–3.6)
Male gender, n (%)	426 (80)	358 (78)	-0.02 (-0.07–0.03)
Body mass index (kg/m <sup>2</sup> )*	26.9 ± 3.6	26.8 ± 4.1	0.2 (-0.6–0.4)
Waist circumference (cm)*	95 ± 11	96 ± 12	0.7 (-0.7–2.0)
Blood pressure (mmHg)*			
Systolic	142 ± 20	145 ± 23	1.4 (1.3–6.8)
Diastolic	82 ± 11	83 ± 12	1.8 (0.4–3.2)
LDL-cholesterol (mmol/L)*	2.8 ± 0.90	2.9 ± 0.97	0.06 (0.05–0.28)
HDL-cholesterol (mmol/L)*	1.31 ± 0.38	1.28 ± 0.37	0.03 (-0.07–0.02)
Triglycerides (mmol/L) <sup>‡</sup>	1.41 (1.05 – 2.07)	1.47 (1.09–2.07)	0.07 (0.03–0.30)
Glucose (mmol/L)*	6.2 ± 1.8	6.4 ± 1.9	0.12 (-0.02–0.45)
HsCRP (mmol/L) <sup>‡</sup>	1.6 (0.8 – 3.5)	1.8 (0.9 - 3.8)	0.60 (-0.80–1.57)
eGFR (ml/min/1.73 m <sup>2</sup> )*	79.7 ± 17.1	75.4 ± 18.6	1.13 (-6.43–2.00)
Homocysteine (µmol/L)*	13.5 ± 4.9	14.6 ± 7.0	0.38 (0.38–1.88)
Prevalent type 2 diabetes, n (%)	71 (13)	85 (19)	-0.05 (-0.10–0.00)
Metabolic syndrome, n (%) <sup>†</sup>	184 (35)	185 (40)	-0.06 (-0.12–0.01)
Smoking, n (%)			
Never	100 (18)	70 (15)	0.04 (-0.01–0.08)
Ever	257 (48)	197 (43)	0.05 (-0.01–0.12)
Current	177 (33)	193 (42)	-0.09 (-0.15–0.03)
Packyears smoking*	23.0 ± 20.1	23.1 ± 21.0	1.31 (-2.51–2.62)
History of vascular disease, n (%)			
Cerebrovascular disease	144 (27)	117 (25)	0.02 (-0.04–0.07)
Coronary artery disease	325 (61)	255 (55)	0.05 (-0.01–0.12)
Peripheral artery disease	108 (20)	133 (29)	-0.09 (-0.14–0.03)
Aneurysm of the abdominal aorta	37 (7)	62 (14)	-0.07 (-0.10–0.03)
Medication, n (%)			
Platelet-aggregation inhibitors	407 (76)	333 (72)	0.04 (-0.02–0.09)
Blood pressure-lowering agents	382 (72)	320 (70)	0.02 (-0.04–0.08)
Lipid-lowering agents	388 (73)	294 (64)	0.09 (0.03–0.14)
Oral anticoagulants	37 (7)	43 (9)	-0.02 (-0.06–0.01)

Values are expressed as: \*Mean ± standard deviation, <sup>‡</sup>Median (interquartile range).

<sup>†</sup>Defined according to the National Cholesterol Education Program ATP III-revised guidelines.

## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract → <a href="#">Title/Abstract</a> (b) Provide in the abstract an informative and balanced summary of what was done and what was found → <a href="#">Abstract</a>
<b>Introduction</b>		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported → <a href="#">Introduction page 3</a>
Objectives	3	State specific objectives, including any prespecified hypotheses → <a href="#">Introduction page 4</a>
<b>Methods</b>		
Study design	4	Present key elements of study design early in the paper → <a href="#">Methods page 4</a>
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection → <a href="#">Methods page 4-5</a>
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up → <a href="#">Methods page 4-5</a> <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable → <a href="#">Methods page 5-6</a>
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group → <a href="#">Methods page 5-6</a>
Bias	9	Describe any efforts to address potential sources of bias → <a href="#">Methods page 6-7</a>
Study size	10	Explain how the study size was arrived at → <a href="#">Methods page 4-5</a>
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why → <a href="#">Methods Page 6</a>
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding → <a href="#">Methods page 7</a> (b) Describe any methods used to examine subgroups and interactions → <a href="#">Methods page 7</a> (c) Explain how missing data were addressed → <a href="#">Methods page 4</a> (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed → <a href="#">Methods page 5</a> <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

sampling strategy

---

(e) Describe any sensitivity analyses

Continued on next page

For peer review only

**Results**

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed → <a href="#">Methods page 4, Results: Table 1</a> (b) Give reasons for non-participation at each stage → <a href="#">Discussion</a> (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders → <a href="#">Results: Table 1; page 7</a> (b) Indicate number of participants with missing data for each variable of interest → <a href="#">N.A</a> (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time → <a href="#">Results: Table 2; page 7-8</a> <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included → <a href="#">Results: Table 2, page 7-8</a> (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses → <a href="#">Results page 7; suppl Table 1</a>

**Discussion**

Key results	18	Summarise key results with reference to study objectives → <a href="#">Discussion page 8</a>
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias → <a href="#">Discussion page 9</a>
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence → <a href="#">Discussion page 10</a>
Generalisability	21	Discuss the generalisability (external validity) of the study results → <a href="#">Discussion page 10</a>

**Other information**

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based → <a href="#">Funding sources page 10</a>
---------	----	---

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).





**Extracellular vesicle protein levels are related to brain atrophy and cerebral white matter lesions in patients with manifest vascular disease: the SMART-MR study**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-003824.R1
Article Type:	Research
Date Submitted by the Author:	14-Nov-2013
Complete List of Authors:	Kanhai, Danny; University Medical Center Utrecht, Vascular Medicine de Kleijn, Dominique Kappelle, Jaap; University Medical Center Utrecht, Neurology Uiterwaal, Cuno; University Medical Centre Utrecht, Epidemiology van der Graaf, Yolanda; Julius Center for Health Sciences and Primary Care Pasterkamp, Gerard; University Medical Center Utrecht, Experimental Cardiology Laboratory Geerlings, Mirjam; Julius Center for Health Sciences and Primary Care Visseren, Frank; University Medical Center Utrecht, Department of Vascular Medicine
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Neurology, Radiology and imaging
Keywords:	extracellular vesicles, White matter lesion, Brain atrophy

SCHOLARONE™  
Manuscripts

only

1  
2  
3 **Extracellular vesicle protein levels are related to brain atrophy and cerebral white**  
4 **matter lesions in patients with manifest vascular disease: the SMART-MR study**  
5  
6

7  
8 Danny A. Kanhai <sup>1</sup>, Dominique P.V. de Kleijn <sup>2,3,4</sup>, L. Jaap Kappelle <sup>5</sup>, Cuno S.P.M. Uiterwaal <sup>6</sup>,  
9 Yolanda van der Graaf <sup>6</sup>, Gerard Pasterkamp <sup>2</sup>, Mirjam I. Geerlings <sup>6</sup>, Frank L.J. Visseren <sup>1</sup>  
10 on behalf of the SMART Study Group\*  
11  
12

13  
14 <sup>1</sup> Department of Vascular Medicine, University Medical Center Utrecht (UMC Utrecht),  
15 Utrecht, The Netherlands  
16

17 <sup>2</sup> Experimental Cardiology Laboratory, UMC Utrecht, Utrecht, The Netherlands  
18

19 <sup>3</sup> Interuniversity Cardiology Institute of the Netherlands (ICIN) Utrecht, the Netherlands  
20

21 <sup>4</sup> Surgery (NUS) and Cardiovascular Research Institute (NUH) Singapore  
22

23 <sup>5</sup> Department of Neurology, Utrecht Stroke Centre, Rudolf Magnus Institute of Neuroscience,  
24 UMC Utrecht, The Netherlands  
25

26 <sup>6</sup> Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht, The Netherlands  
27

28 \* Listed in acknowledgements  
29  
30

31 **Correspondence:**

32 Frank L.J. Visseren, MD, PhD; Department of Vascular Medicine, UMC Utrecht,  
33

34 F02.126, Heidelberglaan 100; 3584 CX Utrecht, The Netherlands  
35

36 Phone: +31 88 75 555 55; Fax: +31 88 75 554 88; e-mail: [f.l.j.visseren@umcutrecht.nl](mailto:f.l.j.visseren@umcutrecht.nl)  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

### *Objectives*

Extracellular vesicles (EVs) and their protein levels have been identified as a potential risk marker for the development of vascular disease. In the present study we assessed whether levels of 4 previously identified EV proteins (Cystatin C, Serpin G1, Serpin F2 and CD14) are associated with cerebral white matter lesions (WML) and brain atrophy.

### *Design*

Cohort study; cross-sectional and prospective

### *Setting*

Single center, secondary and tertiary setting

### *Participants*

1309 Patients with manifest vascular disease from the Second Manifestations of ARterial disease-Magnetic Resonance (SMART-MR) study, of which 994 had successful brain Magnetic Resonance Imaging (MRI) and EV protein level measurements

### *Outcomes*

WML and brain parenchymal fraction (BPF), as parameter for brain atrophy, at baseline and follow-up

### *Statistical methods*

The relation between EV protein levels and WML volume (expressed as log transformed percentage of intracranial volume) and BPF (expressed percentage of intracranial volume) on 1.5 Tesla brain MRI was assessed with multivariable linear regression modeling. Subsequently, the relation between baseline EV protein levels and progression of atrophy and WML was analyzed in 534 patients, in whom a follow-up MRI was obtained after 4 years.

### *Results*

Higher EV-Cystatin C and EV-CD14 were significantly associated with larger WML volume (linear regression coefficient (95% confidence interval) 0.10 log %/SD (0.04 to 0.17) and 0.14 log %/SD (0.07 to 0.20), respectively. Higher EV-CD14 was associated with more brain atrophy (-0.14 % /SD; -0.27 to -0.01). Baseline EV-CD14 was significantly associated with increase of white matter lesions (0.11 log %/SD (0.04–0.18). No relations with EV-Serpins were observed at baseline or at follow-up.

### *Conclusions*

Extracellular vesicle proteins Cystatin C and CD14 are related to cerebral white matter lesions and the progression of brain atrophy in patients with manifest vascular disease, potentially identifying EVs in the etiology of structural brain changes.

## Article summary

### Article focus

- Assess the relationship between specific extracellular vesicle protein levels and structural brain changes
- Clinically important domain of patients with vascular disease
- Etiologic research

### Key Messages

- Extracellular vesicle protein levels are related to cerebral white matter lesions and development of brain atrophy
- Analogous to vascular disease, extracellular vesicles and their protein levels could be causally related to brain changes, potentially identifying a promising novel source of biomarkers in the development of brain changes

### Strengths and limitations

- Relatively large sample size
- Follow-up measurements of brain parameters
- Only four of the numerous protein levels were measured
- Unclear how extracellular vesicles interact with the blood brain barrier

## Introduction

Patients with manifest vascular disease often have morphologic changes in the small vessels of the brain, characterized by white matter lesions (WML) on magnetic resonance imaging (MRI) <sup>1</sup>. The exact underlying pathophysiological mechanism regarding WML remains unclear. WML have been associated with cognitive decline <sup>2</sup> and may explain the increased risk for cognitive decline in patients with manifest vascular disease <sup>3,4</sup>. Cognitive decline and vascular disease have more in common as they share important risk factors such as obesity, hypertension, dyslipidemia and diabetes <sup>5,6</sup>.

Recently, extracellular vesicles (EVs) have been identified as a novel, independent risk marker for the occurrence of vascular disease <sup>7,8</sup>. EVs are membrane shed vesicles, between

1  
2  
3 50 and 1000 nm in diameter, released in the extracellular space after cell activation or  
4 apoptosis, and include various phenotypes such as microparticles and exosomes<sup>9,10</sup>. EVs are  
5 defined by size and antigen expression, which depends on their originating cell type<sup>11,12</sup>.  
6  
7 Release of EVs allows cells to influence (patho)physiological processes over distance in  
8 contrast to cell-cell contact.  
9  
10

11 EVs transfer proteins, mRNA, miRNA and bioactive lipids from one cell to another cell by  
12 either fusion or internalization with target cells<sup>13</sup>. For example, monocyte-derived EVs are  
13 internalized by endothelial cells and activate the nuclear factor- $\kappa$ B pathway and expression of  
14 adhesion molecules on these endothelial cells, amplifying inflammation<sup>14</sup>. EVs are  
15 procoagulant, as they carry phosphatidylserine on their membrane, which facilitates the  
16 assembly of components of the clotting cascade<sup>15</sup>. In addition, EVs also carry the  
17 procoagulant protein tissue factor, which is primary cellular activator of the clotting cascade  
18<sup>16</sup>. It has been demonstrated that atherosclerotic plaques had 200-fold higher levels of EVs in  
19 comparison with plasma of the same study subjects<sup>17</sup>, suggesting an active role of EVs in  
20 atherothrombotic disease rather than a trigger of disease onset.  
21  
22

23 Virtually every cell is capable of producing EVs, including brain cells such as neurons and  
24 astrocytes<sup>18</sup>. Little is known about the role EVs play in the development of brain atrophy or  
25 small vessel disease. However, microparticles, a subclass of EVs, have been shown to  
26 influence arterial stiffness<sup>19</sup>, which is associated with cerebral small vessel disease<sup>20-22</sup>.  
27 Alternatively, platelet derived microparticles have been suggested to play a role in the  
28 formation of cerebral microthrombi<sup>23</sup>, a known initiator of brain atrophy and subsequent  
29 cognitive decline. Exosomes, another subclass of EVs, have been shown to pass the blood-  
30 brain barrier (BBB)<sup>24,25</sup>. In a murine model a specific gene knockdown *in cerebro* was  
31 achieved through the actions of peripherally infused modified exosomes containing specific  
32 RNA<sup>24</sup>.  
33  
34

35 We hypothesized that EV protein levels of Cystatin C, Serpin G1, Serpin F2 and CD14, in  
36 peripherally circulating plasma EVs, which have been related to the occurrence of vascular  
37 disease previously, also are associated with the presence or increase of brain atrophy or with  
38 small vessel disease. Therefore, we investigated the relation between levels of these 4 EV  
39 proteins extracted from plasma, and brain parenchymal fraction (BPF) and white matter  
40 lesions (WML) in a cohort of patients with clinically manifest vascular disease.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Methods

### *SMART-MR study*

The study population consisted of patients participating in the Second Manifestations of ARterial disease-Magnetic Resonance (SMART-MR) study, a prospective cohort study aimed at investigating brain changes on magnetic resonance imaging (MRI) in 1,309 patients with clinically manifest vascular disease. Details of the design and participants have been described elsewhere<sup>1,26</sup>. In brief, between May 2001 and December 2005, all patients newly referred to the University Medical Center Utrecht, The Netherlands with manifest coronary artery disease (CAD), cerebrovascular disease (CVD), peripheral arterial disease (PAD), or an abdominal aortic aneurysm (AAA), and without MR contraindications, were invited to participate. CVD was defined as a recent diagnosis of ischemic stroke, transient ischemic attack or amaurosis fugax. CAD was defined as a recent diagnosis of angina pectoris, myocardial infarction or coronary revascularization (coronary artery bypass graft or coronary angioplasty). PAD consisted of those with a clinical diagnosis of Fontaine stage 2, 3 or 4. AAA was defined as an abdominal aortic aneurysm of  $\geq 3.0$  centimeter or recent aneurysm surgery.

Excluded were patients with a terminal disease, active malignancy, those not independent in daily activities, and those referred back to the referring specialist immediately after 1 visit. After inclusion, patients underwent a standardized vascular screening including assessment of vascular risk factors and non-invasive measurement of subclinical atherosclerosis in addition to MRI of the brain. Risk factors, medical history, and functioning were assessed with questionnaires that the patients completed prior to their visit. Of the original 1309 patients comprising this cohort, 1232 successfully underwent MRI-measurement. For 994 of these patients, material for EV protein level measurement could be retrieved and had at least one EV protein level measurement. Between January 2006 and May 2009, all participants still alive (n = 1,238) were invited for follow-up measurements, including a second MRI of the brain. For 534 patients data on follow-up MRI as well as baseline EV protein levels were available. The SMART-MR study was approved by the ethics committee of the University Medical Center Utrecht, and written informed consent was obtained from all participants.

### *Magnetic resonance imaging protocol*

MR investigations were performed on a 1.5-Tesla whole-body system (Gyrosan ACS-NT, Philips Medical Systems, Best, The Netherlands). The protocol consisted of a transversal T1-weighted gradient-echo sequence (repetition time (TR)/echo time (TE): 235/2 ms; flip angle,

1  
2  
3 80°), a transversal T2-weighted turbo spin-echo sequence (TR/TE: 2200/11 ms and  
4 2200/100 ms; turbo factor 12), a transversal T2-weighted fluid attenuating inverse recovery  
5 (FLAIR) sequence (TR/TE/inversion time (TI): 6000/100/2000 ms), and a transversal  
6 inversion recovery (IR) sequence (TR/TE/TI: 2900/22/410 ms) (field of view mm; matrix size;  
7 slice thickness, 4.0 mm; no gap; 38 slices).  
8  
9  
10

### 11 12 13 *Brain segmentation*

14 The T1-weighted gradient echo, IR sequence, and FLAIR sequence were used for brain  
15 segmentation with the probabilistic segmentation technique that has been described elsewhere  
16 <sup>27,28</sup>. This segmentation program distinguishes cortical gray matter, normal appearing white  
17 matter, sulcal and ventricular cerebrospinal fluid (CSF) and lesions. The results of the  
18 segmentation analysis were visually checked for the presence of infarctions and adapted if  
19 necessary to make a distinction between white matter lesions and infarction volumes. Total  
20 brain volume was calculated by summing the volumes of gray and normal appearing white  
21 matter and, if present, the volumes of WML and infarcts. All volumes cranial to the foramen  
22 magnum were included. As a result, the total brain volume includes both hemispheres,  
23 brainstem, and cerebellum. Total intracranial volume (ICV) was calculated by summing the  
24 total brain volume and the volumes of the sulcal and ventricular CSF.  
25  
26  
27  
28  
29  
30  
31  
32  
33

### 34 35 *White matter lesions*

36 Periventricular WML were defined as WML adjacent to or within one centimeter of the  
37 lateral ventricles. Deep WML were defined as lesions located in deep white matter tracts or  
38 without adjoined periventricular lesions. If white matter hyperintensities on T2-weighted  
39 images were also hypointense on T1-weighted and FLAIR images, they were considered  
40 infarcts and therefore distinguished from WML.  
41  
42  
43  
44  
45

### 46 47 *Brain parameters*

48 Two brain parameters were used for analyses: WML, which was the sum of periventricular  
49 and deep WML in milliliters, expressed as percentage of ICV and brain parenchymal fraction  
50 (BPF), which was determined by calculating the total brain volume in milliliters as percentage  
51 of ICV. By taking percentages of ICV instead of crude brain parameters, correction for  
52 differences in head size was applied.  
53  
54  
55  
56  
57

### 58 59 *Extracellularvesicle measurements* 60

1  
2  
3 Complete measurement methods are described elsewhere <sup>7</sup>. EVs were isolated using  
4 ExoQuick™ (SBI) according to the manufacturer's protocol. Briefly, 150 µl EDTA plasma  
5 was centrifuged for 15 minutes at 3000 g. The supernatant was filtered over a 0.45 µm Spin-X  
6 filter (Corning), which was flushed with preheated PBS (37°C) and 38 µl ExoQuick™  
7 solution was added to the filtrate. After vortexing, the sample was stored overnight at 4°C.  
8  
9 The following day, the sample was centrifuged at 1500 g for 30 minutes at room temperature.  
10  
11 After removing the supernatant, the pellet was lysed in 100 µl Roche Complete Lysis-M with  
12 protease inhibitors (EDTA free). Subsequently, the sample was filtered over a 0.22 µm Spin-  
13 X filter (Corning) and protein level was determined using a Pierce® BCA Protein Assay Kit  
14 (Pierce Biotechnology, Rockford, USA) before storing the sample at -80 °C. After thawing,  
15 the lysed sample was diluted 20x with Roche complete Lysis-M buffer. 50 µl of this diluted  
16 sample was analyzed in a multiplex immuno assay on levels of Cystatin C, Serpin G1, Serpin  
17 F2 & CD14, using a Bio-Rad Bioplex 200 system as described before <sup>29</sup>. Capture antibody,  
18 biotinylated detection antibody and antigen of all 4 proteins were purchased from R&D  
19 systems.  
20  
21  
22  
23  
24  
25  
26  
27  
28

### 29 *Data analyses*

30  
31 Central estimators and their variance measures were calculated for baseline characteristics.  
32  
33 Multivariable linear regression was performed to assess the cross sectional relationship  
34 between EV protein level in pg/ml and WML in % or BPF in %. The fully adjusted model  
35 included age, gender, systolic blood pressure, smoking and type 2 diabetes, as these covariates  
36 are considered to be confounding factors in the suggested relationship between EV protein  
37 levels and measured structural brain changes.  
38  
39 To fulfill linear regression assumptions, WML volumes were naturally log-transformed as  
40 they showed skewed distributions. In order to directly compare strengths of associations,  
41 linear regressions were performed per standard deviation (SD) increase in EV protein level.  
42  
43 Secondly, we assessed the prospective relationship between baseline EV protein levels and  
44 progression in brain parameters on MRI. This was done by relating baseline EV protein levels  
45 to follow-up WML or BPF. Besides adjustment for age, gender, systolic blood pressure,  
46 smoking and type 2 diabetes, these analyses were additionally adjusted for baseline WML or  
47 BPF and follow-up time. Results are expressed as linear regression coefficients and 95%  
48 confidence intervals.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Results

### *Baseline characteristics*

Patient characteristics are displayed in Table 1. Seventy-nine percent of the initial patients were men and the mean age was  $59\pm 10$  years. The majority of the patients had a (recent) medical history of CAD (58%), followed by CVD (26%), PAD (24%) and AAA (10%). After a mean interval time of  $3.9\pm 0.4$  years, 534 patients underwent a second MRI of the brain. This follow-up cohort comprised 80% men and a mean baseline age of  $58\pm 9$  years, which corresponded with a mean follow-up age of  $62\pm 9$  years. For the baseline comparisons of the two groups, we refer to supplemental Table 1.

### *Cross-sectional association between EV protein levels and WML or BPF*

In the fully adjusted model, higher EV-Cystatin C and EV-CD14 were associated with more volume of WML. Regression coefficients per SD EV-protein were 0.10 (95%CI 0.04-0.17) for EV-Cystatin C and 0.14 (95%CI 0.07–0.20) for EV-CD14 (Table 2). Also, higher EV-CD14 was associated with a statistically significantly lower BPF (regression coefficient per SD EV-CD14 -0.14 (95%CI -0.27–0.01)); (Table 3). SD increases of EV-Serpin G1 and EV-Serpin F2 were not related with WML or BPF at baseline.

In general, adjustment for age and gender in model 2 altered the effect estimates substantially, whereas the impact that systolic blood pressure, smoking and type 2 diabetes had on the occurrence relation was relatively small. Tests for interaction by age and gender yielded non-significant results (data not shown).

### *Prospective associations between EV protein levels and of WML or BPF*

In the fully adjusted model, higher EV-CD14 was associated with increase of WML volume (regression coefficient = 0.11 (95%CI 0.04-0.18)) as is displayed in Table 2. EV-Cystatin C, EV-Serpin G1 and EV-Serpin F2 were not related with increase of WML or BPF.

## Discussion

In patients with various clinical manifestations of vascular disease, EV protein levels of Cystatin C and CD14 in plasma are associated with larger WML and more brain atrophy. Furthermore, higher EV-CD 14 levels are associated with an increase in WML during 4 years

1  
2  
3 of follow-up. This relation is independent of age, gender, systolic blood pressure, smoking  
4 and type 2 diabetes.

5  
6 The role of Cystatin C, a cysteine protease inhibitor, in the process of degenerative disorders  
7 in the brain is unclear. In vitro and murine studies have shown that Cystatin C binds to  
8 amyloid- $\beta$  ( $\text{a}\beta$ ), resulting in inhibition of  $\text{a}\beta$  deposition<sup>30-32</sup>, the characteristic component of  
9 the neuritic plaques that identify patients with Alzheimer's disease. This protective role of  
10 Cystatin C was supported in a cohort study<sup>33</sup>, where lower levels of serum Cystatin C were  
11 associated with higher risk for future Alzheimer's disease in men. However, higher levels of  
12 serum Cystatin C have also been associated with cognitive decline<sup>34,35</sup> and with WML<sup>36</sup> in  
13 large population-based cohort studies. In WML, the Cystatin C expression is upregulated in  
14 astrocytes, presumably due to a self-defense response in the process of white matter  
15 degeneration<sup>37</sup>. Our results, based upon EV-Cystatin C, show similar results as increasing EV-  
16 Cystatin C is related to increased volume of WML. Cystatin C is secreted by all human tissues  
17<sup>38</sup>, which presumably concomitantly shed Cystatin C<sup>+</sup> EVs in order to directly influence more  
18 distant processes.

19  
20 CD14 is a cofactor for Toll-like receptor 4 (TLR4), which regulates NF $\kappa$ B expression,  
21 indicating a role for CD14 in inflammation<sup>39</sup>. CD14 is expressed on monocytes<sup>40</sup>, and it is  
22 therefore assumable that CD14<sup>+</sup> EVs originate from these monocytes. In our study, EV-CD14  
23 levels were related to the volume and increase of WML. This indicates a EV-initiated  
24 inflammatory response in dealing with WML. These findings do not stand alone as several  
25 inflammatory biomarkers such as lipoprotein-associated phospholipase A2 (Lp-PLA2) and  
26 myeloperoxidase (MPO), have been associated with WML<sup>41</sup>. Although the effects of EV-  
27 CD14 on WML and BPF have not been assessed previously, soluble CD14 has been  
28 associated with cognitive impairment and brain atrophy in patients with HIV<sup>42</sup>. Likewise,  
29 higher plasma levels of EV-CD14 were inversely related to BPF at baseline in our study.  
30 EV-Serpin G1 (C1-inhibitor) and EV-Serpin F2 ( $\alpha$ 2-antiplasmin) were not associated with  
31 WML or BPF in our study, suggesting no substantial role of (inhibited) fibrinolysis in the  
32 pathophysiology surrounding WML or brain atrophy. To our understanding this is the first  
33 report on these Serpins and their potential role in the etiology of WML and brain atrophy.  
34 Whether and how EVs or EV protein levels might directly influence ischemic white matter  
35 lesions or brain volume is not known. Several mechanisms are proposed. We assume that EVs  
36 have blood-brain barrier penetrating properties, based upon recent data regarding exosomes<sup>24,</sup>  
37<sup>25</sup>. It could also be that EVs interact with endothelial cells through receptor-mediated  
38 endocytosis. Once fused with these endothelial cells, EV protein levels might activate  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 inflammation cascade signaling, leading to vascular damage and subsequent arterial stiffness.  
4  
5 It might also activate hemostasis cascade signaling leading to the formation of  
6 (micro)thrombi. Alternatively, through endocytosis by endothelial cells, EV protein levels  
7  
8 might influence the structural integrity of the endothelial layer resulting in greater BBB  
9 permeability. Neurodegenerative disorders as Alzheimer disease<sup>43</sup> and multiple sclerosis<sup>44</sup>  
10  
11 have been associated with BBB integrity loss. The mechanism behind this loss is unclear and  
12 perhaps EV vesicles play a role within this process. Future work will have to test these  
13 hypotheses. If true causation between EV protein levels and brain changes would be the case,  
14 strategies on influencing EV protein levels should be developed.  
15  
16

17  
18 Strengths of the present prospective cohort study include the relatively large sample size with  
19 various EV protein measurements and MRIs of the brain at baseline and 3.9 years follow up,  
20 which makes reversed causality less likely. Another strength of the study is the use of  
21 automated segmentation techniques to obtain brain parameters, which provides more precise  
22 and objective estimates than visual rating scales<sup>45</sup> and enables accurate measurement of small  
23 volume changes over time<sup>46</sup>.  
24  
25  
26

27  
28 Potential study limitations should also be considered. First, data of only 54% of the surviving  
29 cohort was used to measure change in WML or BPF. The patients who were physically able  
30 to undergo the follow-up MRI were most likely healthier than those who did not participate,  
31 which might have led to dilution of associations. Secondly, only 4 of the numerous proteins  
32 on the surface or within EVs were measured. It could well be that besides these vascular risk  
33 markers, various other EV proteins have their etiology in the structural brain changes.  
34  
35

36  
37 Thirdly, we assume that plasma EVs which hold the proteins measured in the present study  
38 have the ability to cross the BBB in order to have their effects on the brain, influencing WML  
39 and BPF. Unfortunately no data is available whether these EVs are indeed present within the  
40 brain and it would be interesting to know if these EV proteins are present in cerebrospinal  
41 fluid and have a non-cerebral origin. If these EVs can truly pass the BBB and influence  
42 pathophysiological processes in the brain, it automatically gives rise to potential therapeutical  
43 purposes analogous to exosomes, as these vesicles can deliver complex drugs directly into the  
44 brain, a key step in the treatment of brain diseases or brain changes<sup>47</sup>.  
45  
46  
47  
48

49  
50 In conclusion, EV-Cystatin C and EV-CD14 levels are related with the volume of WML and  
51 with BPF on brain MRI. EV-CD14 levels are related with an increase in the total volume of  
52 WML during follow-up. Extracellular vesicle proteins levels may be causally related to brain  
53 changes in patients with clinically manifest vascular disease.  
54  
55  
56  
57  
58  
59  
60

### Acknowledgments

We gratefully acknowledge the members of the SMART study group of UMC Utrecht: P.A. Doevendans, MD, PhD, Department of Cardiology; A. Algra, MD, PhD; Y. van der Graaf, MD, PhD; D.E. Grobbee, MD, PhD, G.E.H.M. Rutten, MD, PhD, Julius Center for Health Sciences and Primary Care; L.J. Kappelle, MD, PhD, Department of Neurology; W.P.T.M. Mali, MD, PhD, Department of Radiology; F.L. Moll, MD, PhD, Department of Vascular Surgery; F.L.J. Visseren, MD, PhD, Department of Vascular Medicine.

We thank, A.H. Schoneveld, L. Collee and S. van der Weg for the measurement of the plasma extracellular vesicle proteins.

### Contributorship Statement

- Conception and design, or analysis and interpretation of data: DAK, LJK, CSPMU, FLJV
- Drafting the article or revising it critically for important intellectual content: DAK, DPVdK, LJK, CSPMU, YvdG, GP, MIG, FLJV
- Final approval of the version to be published: DAK, DPVdK, LJK, CSPMU, YvdG, GP, MIG, FLJV

### Funding sources

This work was financially supported by the UMC Utrecht Vascular Prevention Project.

### Disclosures

The authors declare no conflict of interest.

### Data Sharing Statement

Additional unpublished data from the SMART-study in general are available to all members of the SMART study group.

## References

1. Geerlings MI, Appelman AP, Vincken KL, et al. Brain volumes and cerebrovascular lesions on MRI in patients with atherosclerotic disease. The SMART-MR study. *Atherosclerosis*. 2010; 210:130–136.
2. Breteler MM, van Swieten JC, Bots ML, et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. *Neurology*. 1994;44:1246-52.
3. Vinkers DJ, Stek ML, van der Mast RC, et al. Generalized atherosclerosis, cognitive decline, and depressive symptoms in old age. *Neurology*. 2005;65:107-12.
4. Breteler MM, Claus JJ, Grobbee DE, et al. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. *BMJ*. 1994;308:1604-8.
5. Nash DT, Fillit H. Cardiovascular disease risk factors and cognitive impairment. *Am J Cardiol*. 2006;97:1262-5.
6. Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia: how to move forward? *Neurology*. 2009;72:368-74.
7. Kanhai DA, Visseren FL, van der Graaf Y, et al. Microvesicle protein levels are associated with increased risk for future vascular events and mortality in patients with clinically manifest vascular disease. *Int. J. Cardiol*. 2013;3;168:2358-63.
8. Sinning JM, Losch J, Walenta K, et al. Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. *Eur Heart J*. 2011;32:2034-2041.
9. Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. *Trends Cell Biol*. 2009;19:43-51.
10. van der Vlist EJ, Nolte-'t Hoen EN, Stoorvogel W, et al. Fluorescent labeling of nano-sized vesicles released by cells and subsequent quantitative and qualitative analysis by high-resolution flow cytometry. *Nat Protoc*. 2012;7:1311-26.

- 1  
2  
3  
4  
5 11. Jy W, Horstman LL, Jimenez JJ, et al. Measuring circulating cell-derived microparticles. *J*  
6 *Thromb Haemost.* 2004;2:1842–1851.  
7  
8  
9  
10 12. Morel O, Morel N, Hugel B, et al. The significance of circulating microparticles in  
11 physiology, inflammatory and thrombotic diseases. *Rev Med Interne.* 2005;26:791–801.  
12  
13  
14 13. Martinez MC, Tual-Chalot S, Leonetti D, et al. Microparticles: targets and tools in  
15 cardiovascular disease. *Trends Pharmacol Sci.* 2011;32:659-65.  
16  
17  
18  
19 14. Wang JG, Williams JC, Davis BK, et al. Monocytic microparticles activate endothelial  
20 cells in an IL-1 $\beta$ -dependent manner. *Blood.* 2011;118:2366-74.  
21  
22  
23  
24 15. Owens AP 3rd, Mackman N. Microparticles in hemostasis and thrombosis. *Circ Res.*  
25 2011;108:1284-97.  
26  
27  
28  
29 16. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in  
30 hemostasis and thrombosis. *Arterioscler Thromb Vasc Biol.* 2007;27:1687-93.  
31  
32  
33  
34 17. Leroyer AS, Isobe H, Lesèche G, et al. Cellular origins and thrombogenic activity of  
35 microparticles isolated from human atherosclerotic plaques. *J Am Coll Cardiol.* 2007;49:772-  
36 7.  
37  
38  
39  
40  
41 18. Fauré J, Lachenal G, Court M, et al. Exosomes are released by cultured cortical neurones.  
42 *Mol Cell Neurosci.* 2006;31:642-8.  
43  
44  
45  
46 19. Amabile N, Guérin AP, Leroyer A, et al. Circulating endothelial microparticles are  
47 associated with vascular dysfunction in patients with end-stage renal failure. *J Am Soc*  
48 *Nephrol.* 2005;16:3381-8.  
49  
50  
51  
52  
53 20. O'Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular  
54 disease in brain and kidney: cause and logic of therapy. *Hypertension.* 2005;46:200 –204.  
55  
56  
57  
58  
59  
60

- 1  
2  
3 21. Ohmine T, Miwa Y, Yao H, et al. Association between arterial stiffness and cerebral  
4 white matter lesions in community-dwelling elderly subjects. *Hypertens Res.* 2008;31:75– 81.  
5  
6  
7  
8 22. Kuo HK, Chen CY, Liu HM, et al. Metabolic risks, white matter hyperintensities, and  
9 arterial stiffness in high-functioning healthy adults. *Int J Cardiol.* 2010;143:184 –191.  
10  
11  
12  
13 23. Jimenez JJ, Jy W, Mauro LM, et al. Elevated endothelial microparticles in thrombotic  
14 thrombocytopenic purpura: findings from brain and renal microvascular cell culture and  
15 patients with active disease. *Br J Haematol.* 2001;112:81-90.  
16  
17  
18  
19 24. Alvarez-Erviti L, Seow Y, Yin H, et al. Delivery of siRNA to the mouse brain by systemic  
20 injection of targeted exosomes. *Nat Biotechnol.* 2011;29:341-5.  
21  
22  
23  
24 25. Graner MW, Alzate O, Dechkovskaia AM, et al, Bigner DD. Proteomic and immunologic  
25 analyses of brain tumor exosomes. *FASEB J.* 2009;23:1541-57.  
26  
27  
28  
29 26. Simons PC, Algra A, van de Laak MF, et al. Second manifestations of ARterial disease  
30 (SMART) study: rationale and design. *Eur J Epidemiol.* 1999;15:773-781.  
31  
32  
33  
34 27. Anbeek P, Vincken KL, van Osch MJ, et al. Probabilistic segmentation of white matter  
35 lesions in MR imaging. *Neuroimage.* 2004;21:1037-44.  
36  
37  
38  
39 28. Anbeek P, Vincken KL, van Bochove GS, et al. Probabilistic segmentation of brain tissue  
40 in MR imaging. *Neuroimage.* 2005;27:795-804.  
41  
42  
43  
44 29. Schipper HS, de Jager W, van Dijk ME, et al. A multiplex immunoassay for human  
45 adipokine profiling. *Clin Chem.* 2010;56:1320-8.  
46  
47  
48  
49 30. Sastre M, Calero M, Pawlik M, et al. Binding of cystatin C to Alzheimer's amyloid beta  
50 inhibits in vitro amyloid fibril formation. *Neurobiol Aging.* 2004;25:1033-43.  
51  
52  
53  
54 31. Kaeser SA, Herzig MC, Coomaraswamy J, et al. Cystatin C modulates cerebral beta-  
55 amyloidosis. *Nat Genet.* 2007;39:1437-9.  
56  
57  
58  
59  
60

- 1  
2  
3 32. Mi W, Pawlik M, Sastre M, et al. Cystatin C inhibits amyloid-beta deposition in  
4 Alzheimer's disease mouse models. *Nat Genet.* 2007 ;39:1440-2.  
5  
6  
7  
8 33. Sundelöf J, Arnlöv J, Ingelsson E, et al. Serum cystatin C and the risk of Alzheimer  
9 disease in elderly men. *Neurology.* 2008;71:1072-9.  
10  
11  
12  
13 34. Yaffe K, Lindquist K, Shlipak MG, et al. Cystatin C as a marker of cognitive function in  
14 elders: findings from the health ABC study. *Ann Neurol.* 2008;63:798-802.  
15  
16  
17  
18 35. Rajagopalan P, Refsum H, Hua X, et al. Alzheimer's Disease Neuroimaging Initiative.  
19 Mapping creatinine- and cystatin C-related white matter brain deficits in the elderly.  
20 *Neurobiol Aging.* 2012; [Epub ahead of print]  
21  
22  
23  
24  
25  
26 36. Wada M, Nagasawa H, Kawanami T, et al. Cystatin C as an index of cerebral small vessel  
27 disease: results of a cross-sectional study in community-based Japanese elderly. *Eur J Neurol.*  
28 2010;17:383-90.  
29  
30  
31  
32  
33 37. Umegae N, Nagai A, Terashima M, et al. Cystatin C expression in ischemic white matter  
34 lesions. *Acta Neurol Scand.* 2008;118:60-7.  
35  
36  
37  
38 38. Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C. *Crit Rev Clin*  
39 *Lab Sci.* 2004;41:467-550.  
40  
41  
42  
43 39. Jiang Q, Akashi S, Miyake K, et al. Lipopolysaccharide induces physical proximity  
44 between CD14 and toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-kappa B. *J*  
45 *Immunol.* 2000;165:3541-4.  
46  
47  
48  
49 40. Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic  
50 cells in blood. *Blood.* 2010;116:e74-80.  
51  
52  
53  
54 41. Wright CB, Moon Y, Paik MC, et al. Inflammatory biomarkers of vascular risk as  
55 correlates of leukoariorosis. *Stroke.* 2009;40:3466-71.  
56  
57  
58  
59  
60



- 1  
2  
3 42. Ryan LA, Zheng J, Brester M, et al. Plasma levels of soluble CD14 and tumor necrosis  
4 factor-alpha type II receptor correlate with cognitive dysfunction during human  
5 immunodeficiency virus type 1 infection. *J Infect Dis.* 2001;184:699-706.  
6  
7  
8  
9  
10 43. Zipser BD, Johanson CE, Gonzalez L, et al. Microvascular injury and blood-brain barrier  
11 leakage in Alzheimer's disease. *Neurobiol Aging.* 2007;28:977-86.  
12  
13  
14 44. Waubant E. Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis.  
15 *Dis Markers.* 2006;22:235-44.  
16  
17  
18  
19 45. Yoshita M, Fletcher E, DeCarli C. Current concepts of analysis of cerebral white matter  
20 hyperintensities on magnetic resonance imaging. *Top Magn Reson Imaging.* 2005;16:399-  
21 407.  
22  
23  
24  
25  
26 46. van den Heuvel DM, ten Dam VH, de Craen AJ, et al. PROSPER Study Group.  
27 Measuring longitudinal white matter changes: comparison of a visual rating scale with a  
28 volumetric measurement. *Am J Neuroradiol.* 2006;27:875-8.  
29  
30  
31  
32  
33 47. Wood MJ, O'Loughlin AJ, Samira L. Exosomes and the blood-brain barrier: implications  
34 for neurological diseases. *Ther Deliv.* 2011;2:1095-9.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1: Baseline patient characteristics**

	Baseline cohort N = 994	Follow-up patients N = 534	Non-FU patients N = 460
Age (years)*	59 ± 10	58 ± 9	60 ± 11
Male gender, n (%)	784 (79)	426 (80)	358 (78)
Body mass index (kg/m <sup>2</sup> )*	26.9 ± 3.8	26.9 ± 3.6	26.8 ± 4.1
Waist circumference (cm)*	95 ± 11	95 ± 11	96 ± 12
Blood pressure (mmHg)*			
Systolic	144 ± 22	142 ± 20	145 ± 23
Diastolic	83 ± 12	82 ± 11	83 ± 12
LDL-cholesterol (mmol/L)*	2.8 ± 0.93	2.8 ± 0.90	2.9 ± 0.97
HDL-cholesterol (mmol/L)*	1.30 ± 0.38	1.31 ± 0.38	1.28 ± 0.37
Triglycerides (mmol/L) <sup>‡</sup>	1.47 (1.09 – 2.07)	1.41 (1.05 – 2.07)	1.47 (1.09-2.07)
Glucose (mmol/L)*	6.3 ± 1.9	6.2 ± 1.8	6.4 ± 1.9
HsCRP (mmol/L) <sup>‡</sup>	1.8 (0.9 – 3.8)	1.6 (0.8 – 3.5)	1.8 (0.9 - 3.8)
eGFR (ml/min/1.73 m <sup>2</sup> )*	77.7 ± 17.9	79.7 ± 17.1	75.4 ± 18.6
Homocysteine (µmol/L)*	14.0 ± 6.0	13.5 ± 4.9	14.6 ± 7.0
Prevalent type 2 diabetes, n (%)	156 (16)	71 (13)	85 (19)
Metabolic syndrome, n (%) <sup>†</sup>	369 (37)	184 (35)	185 (40)
Smoking, n (%)			
Never	170 (17)	100 (18)	70 (15)
Ever	454 (46)	257 (48)	197 (43)
Current	370 (37)	177 (33)	193 (42)
Packyears smoking*	23.0 ± 20.5	23.0 ± 20.1	23.1 ± 21.0
History of vascular disease, n (%)			
Cerebrovascular disease	261 (26)	144 (27)	117 (25)
Coronary artery disease	580 (58)	325 (61)	255 (55)
Peripheral artery disease	241 (24)	108 (20)	133 (29)
Aneurysm of the abdominal aorta	99(10)	37 (7)	62 (14)
Medication, n (%)			
Platelet-aggregation inhibitors	740 (74)	407 (76)	333 (72)
Blood pressure-lowering agents	702 (71)	382 (72)	320 (70)
Lipid-lowering agents	682 (69)	388 (73)	294 (64)
Oral anticoagulants	80 (8)	37 (7)	43 (9)
White matter lesions (log%)*	-2,1 (1.1)	-2,3 (1.1)	-1.9 (1.1)
Brain parenchymal fraction (%)*	79 (3)	79 (3)	79 (3)

Values are expressed as: \*Mean ± standard deviation, <sup>‡</sup>Median (interquartile range).

<sup>†</sup>Defined according to the National Cholesterol Education Program ATP III-revised guidelines.

**Table 2: Extracellular vesicle protein levels and white matter lesions (WML)**

	Model	WML	
		WML at baseline n=994	WML at follow-up* n= 534
EV-Cystatin C (pg/μg)	I	<b>0.27 (0.20 – 0.34)</b>	0.06 (-0.02 – 0.13)
Mean 10.6	II	<b>0.10 (0.04 – 0.17)</b>	0.01 (-0.06 – 0.08)
SD 5.3	III	<b>0.10 (0.04 – 0.17)</b>	0.01 (-0.06 – 0.08)
EV-Serpin G1 (pg/μg)	I	-0.03 (-0.10 – 0.05)	0.02 (-0.05 – 0.08)
Mean 142.2	II	-0.02 (-0.08 – 0.04)	0.02 (-0.04 – 0.08)
SD 85.6	III	-0.03 (-0.08 – 0.05)	0.03 (-0.03 – 0.09)
EV-Serpin F2 (pg/μg)	I	0.01 (-0.066 – 0.08)	-0.01 (-0.08 – 0.05)
Mean 43.3	II	0.03 (-0.034 – 0.09)	0.01 (-0.06 – 0.07)
SD 30.4	III	0.03 (-0.035 – 0.09)	0.01 (-0.05 – 0.07)
EV-CD 14 (pg/μg)	I	<b>0.23 (0.16 – 0.30)</b>	<b>0.12 (0.04 – 0.18)</b>
Mean 12.2	II	<b>0.14 (0.08 – 0.20)</b>	<b>0.10 (0.03 – 0.17)</b>
SD 3.9	III	<b>0.14 (0.07 – 0.20)</b>	<b>0.11 (0.04 – 0.18)</b>

Regression coefficients: increase in WML (log%) per 1SD increase in EV protein level (pg/ml)

Model I: Univariable model

Model II: Adjustment for age and gender

Model III: Model II with additional adjustment for systolic blood pressure, packyears smoking and prevalent type 2 diabetes mellitus

\*Models include additional adjustment for baseline WML and follow-up time

**Table 3: Extracellular vesicle protein levels and Brain Parenchymal Fraction (BPF)**

	Model	BPF	
		BPF at baseline n=994	BPF at follow-up* n= 534
EV-Cystatin C (pg/μg)	I	<b>-0.69 (-0.86 - -0.51)</b>	<b>-0.15 (-0.26 - -0.04)</b>
<i>Mean 10.6</i>	II	-0.12 (-0.26 - 0.02)	-0.06 (-0.16 - 0.04)
<i>SD 5.3</i>	III	-0.11 (-0.24 - 0.03)	-0.05 (-0.16 - 0.05)
EV-Serpin G1 (pg/μg)	I	-0.00 (-0.18 - 0.17)	0.04 (-0.05 - 0.14)
<i>Mean 142.2</i>	II	0.01 (-0.12 - 0.14)	0.02 (-0.06 - 0.11)
<i>SD 85.6</i>	III	0.10 (-0.12 - 0.14)	0.03 (-0.06 - 0.11)
EV-Serpin F2 (pg/μg)	I	0.05 (-0.12 - 0.23)	0.06 (-0.04 - 0.16)
<i>Mean 43.3</i>	II	-0.10 (-0.23 - 0.03)	-0.01 (-0.10 - 0.08)
<i>SD 30.4</i>	III	-0.06 (-0.19 - 0.07)	0.01 (-0.09 - 0.10)
EV-CD 14 (pg/μg)	I	<b>-0.45 (-0.62 - -0.28)</b>	-0.06 (-0.17 - 0.05)
<i>Mean 12.2</i>	II	<b>-0.19 (-0.32 - -0.06)</b>	-0.05 (-0.15 - 0.05)
<i>SD 3.9</i>	III	<b>-0.14 (-0.27 - -0.01)</b>	-0.03 (-0.13 - 0.07)

Regression coefficients: increase in BPF (%) per 1SD increase in EV protein level (pg/ml)

Model I: Univariable model

Model II: Adjustment for age and gender

Model III: Model II with additional adjustment for systolic blood pressure, packyears smoking and prevalent type 2 diabetes mellitus

\*Models include additional adjustment for baseline WML and follow-up time

1  
2  
3  
4  
5  
6  
7 **Micovesicle-Extracellular vesicle protein levels are related to brain atrophy and**  
8 **cerebral white matter lesions in patients with manifest vascular disease: the SMART-MR**  
9 **study**  
10

11  
12 Danny A. Kanhai <sup>1</sup>, Dominique P.V. de Kleijn <sup>2,3,4</sup>, L. Jaap Kappelle <sup>5</sup>, Cuno S.P.M. Uiterwaal <sup>6</sup>,  
13 Yolanda van der Graaf <sup>6</sup>, Gerard Pasterkamp <sup>2</sup>, Mirjam I. Geerlings <sup>6</sup>, Frank L.J. Visseren <sup>1</sup>  
14 on behalf of the SMART Study Group\*  
15  
16

17  
18 <sup>1</sup> Department of Vascular Medicine, University Medical Center Utrecht (UMC Utrecht),  
19 Utrecht, The Netherlands

20  
21 <sup>2</sup> Experimental Cardiology Laboratory, UMC Utrecht, Utrecht, The Netherlands

22  
23 <sup>3</sup> Interuniversity Cardiology Institute of the Netherlands (ICIN) Utrecht, the Netherlands

24  
25 <sup>4</sup> Surgery (NUS) and Cardiovascular Research Institute (NUH) Singapore

26  
27 <sup>5</sup> Department of Neurology, Utrecht Stroke Centre, Rudolf Magnus Institute of Neuroscience,  
28 UMC Utrecht, The Netherlands

29  
30 <sup>6</sup> Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht, The Netherlands

31  
32 \* Listed in acknowledgements

33 **Correspondence:**

34 Frank L.J. Visseren, MD, PhD; Department of Vascular Medicine, UMC Utrecht,  
35 F02.126, Heidelberglaan 100; 3584 CX Utrecht, The Netherlands

36  
37 Phone: +31 88 75 555 55; Fax: +31 88 75 554 88; e-mail: [f.l.j.visseren@umcutrecht.nl](mailto:f.l.j.visseren@umcutrecht.nl)  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

### *Objectives*

Microvesicles-Extracellular vesicles (MVEVs) and their protein levels have been identified as a potential risk marker for the development of vascular disease. In the present study we assessed whether levels of 4 previously identified MVEV proteins (Cystatin C, Serpin G1, Serpin F2 and CD14) are associated with cerebral white matter lesions (WML) and brain atrophy.

### *Design*

Cohort study; cross-sectional and prospective

### *Setting*

Single center, secondary and tertiary setting

### *Participants*

1309 Patients with manifest vascular disease from the Second Manifestations of ARterial disease-Magnetic Resonance (SMART-MR) study, of which 994 had successful brain Magnetic Resonance Imaging (MRI) and MVEV protein level measurements

### *Outcomes*

WML and brain parenchymal fraction (BPF), as parameter for brain atrophy, at baseline and follow-up

### *Statistical methods*

The relation between MVEV protein levels and WML volume (expressed as log transformed percentage of intracranial volume) and BPF (expressed percentage of intracranial volume) on 1.5 Tesla brain MRI was assessed with multivariable linear regression modeling. Subsequently, the relation between baseline MVEV protein levels and progression of atrophy and WML was analyzed in 534 patients, in whom a follow-up MRI was obtained after 4 years.

### *Results*

Higher MVEV-Cystatin C and MVEV-CD14 were significantly associated with larger WML volume (linear regression coefficient (95% confidence interval) 0.10 log %/SD (0.04 to 0.17) and 0.14 log %/SD (0.07 to 0.20), respectively. Higher MVEV-CD14 was associated with more brain atrophy (-0.14 % /SD; -0.27 to -0.01). Baseline MVEV-CD14 was significantly associated with increase of white matter lesions (0.11 log %/SD (0.04–0.18). No relations with MVEV-Serpins were observed at baseline or at follow-up.

### *Conclusions*

1  
2  
3  
4  
5  
6  
7 | Extracellular Microvesicle proteins Cystatin C and CD14 are related to cerebral white matter  
8 lesions and the progression of brain atrophy in patients with manifest vascular disease,  
9 | potentially identifying MVEVs in the etiology of structural brain changes.

## 10 11 12 **Article summary**

### 13 14 15 Article focus

- 16 • Assess the relationship between specific extracellular vesicle protein levels and
- 17 structural brain changes
- 18 • Clinically important domain of patients with vascular disease
- 19 • Etiologic research

### 20 21 22 Key Messages

- 23 • Extracellular vesicle protein levels are related to cerebral white matter lesions and
- 24 development of brain atrophy
- 25 • Analogous to vascular disease, extracellular vesicles and their protein levels could be
- 26 causally related to brain changes, potentially identifying a promising novel source of
- 27 biomarkers in the development of brain changes

### 28 29 30 Strengths and limitations

- 31 • Relatively large sample size
- 32 • Follow-up measurements of brain parameters
- 33 • Only four of the numerous protein levels were measured
- 34 • Unclear how extracellular vesicles interact with the blood brain barrier

## 35 36 37 **Introduction**

38 Patients with manifest vascular disease often have morphologic changes in the small vessels  
39 of the brain, characterized by white matter lesions (WML) on magnetic resonance imaging  
40 (MRI) <sup>1</sup>. The exact underlying pathophysiological mechanism regarding WML remains  
41 unclear. WML have been associated with cognitive decline <sup>2</sup> and may explain the increased  
42 risk for cognitive decline in patients with manifest vascular disease <sup>3,4</sup>. Cognitive decline and  
43

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

vascular disease have more in common as they share important risk factors such as obesity, hypertension, dyslipidemia and diabetes<sup>5,6</sup>.

Recently, extracellular microvesicles (MVEVs) have been identified as a novel, independent risk marker for the occurrence of vascular disease<sup>7,8</sup>. MVEVs are membrane shed vesicles, between 50 and 1000 nm in diameter, released in the extracellular space after cell activation or apoptosis, and include various phenotypes such as microparticles and exosomes<sup>9,10</sup>.

MVEVs are defined by size and antigen expression, which depends on their originating cell type<sup>11,12</sup>. Release of MVEVs allows cells to influence (patho)physiological processes over distance in contrast to cell-cell contact.

MVEVs transfer proteins, mRNA, miRNA and bioactive lipids from one cell to another cell by either fusion or internalization with target cells<sup>13</sup>. For example, monocyte-derived

MVEVs are internalized by endothelial cells and activate the nuclear factor- $\kappa$ B pathway and expression of adhesion molecules on these endothelial cells, amplifying inflammation<sup>14</sup>.

MVEVs are procoagulant, as they carry phosphatidylserine on their membrane, which facilitates the assembly of components of the clotting cascade<sup>15</sup>. In addition, MVEVs also carry the procoagulant protein tissue factor, which is primary cellular activator of the clotting cascade<sup>16</sup>. It has been demonstrated that atherosclerotic plaques had 200-fold higher levels of MVEVs in comparison with plasma of the same study subjects<sup>17</sup>, suggesting an active role of MVEVs in atherothrombotic disease rather than a trigger of disease onset.

Virtually every cell is capable of producing MVEVs, including brain cells such as neurons and astrocytes<sup>18</sup>. Little is known about the role MVEVs play in the development of brain atrophy or small vessel disease. However, microparticles, a subclass of MVEVs, have been shown to influence arterial stiffness<sup>19</sup>, which is associated with cerebral small vessel disease<sup>20-22</sup>. Alternatively, platelet derived microparticles have been suggested to play a role in the formation of cerebral microthrombi<sup>23</sup>, a known initiator of brain atrophy and subsequent cognitive decline. Exosomes, another subclass of MVEVs, have been shown to pass the blood-brain barrier (BBB)<sup>24,25</sup>. In a murine model a specific gene knockdown *in cerebro* was achieved through the actions of peripherally infused modified exosomes containing specific RNA<sup>24</sup>.

We hypothesized that MVEV protein levels of Cystatin C, Serpin G1, Serpin F2 and CD14, in peripherally circulating plasma MVEVs, which have been related to the occurrence of vascular disease previously, also are associated with the presence or increase of brain atrophy or with small vessel disease. Therefore, we investigated the relation between levels of these 4 MVEV proteins extracted from plasma, and brain parenchymal fraction (BPF) and white



1  
2  
3  
4  
5  
6  
7 matter lesions (WML) in a cohort of patients with clinically manifest vascular disease.  
8  
9

## 10 11 **Methods**

### 12 *SMART-MR study*

13  
14 The study population consisted of patients participating in the Second Manifestations of  
15 ARterial disease-Magnetic Resonance (SMART-MR) study, a prospective cohort study  
16 aimed at investigating brain changes on magnetic resonance imaging (MRI) in 1,309 patients  
17 with clinically manifest vascular disease. Details of the design and participants have been  
18 described elsewhere<sup>1, 26</sup>. In brief, between May 2001 and December 2005, all patients newly  
19 referred to the University Medical Center Utrecht, The Netherlands with manifest coronary  
20 artery disease (CAD), cerebrovascular disease (CVD), peripheral arterial disease (PAD), or an  
21 abdominal aortic aneurysm (AAA), and without MR contraindications, were invited to  
22 participate. CVD was defined as a recent diagnosis of ischemic stroke, transient ischemic  
23 attack or amaurosis fugax. CAD was defined as a recent diagnosis of angina pectoris,  
24 myocardial infarction or coronary revascularization (coronary artery bypass graft or coronary  
25 angioplasty). PAD consisted of those with a clinical diagnosis of Fontaine stage 2, 3 or 4.  
26 AAA was defined as an abdominal aortic aneurysm of  $\geq 3.0$  centimeter or recent aneurysm  
27 surgery.  
28

29 Excluded were patients with a terminal disease, active malignancy, those not independent in  
30 daily activities, and those referred back to the referring specialist immediately after 1 visit.  
31

32 After inclusion, patients underwent a standardized vascular screening including assessment of  
33 vascular risk factors and non-invasive measurement of subclinical atherosclerosis in addition  
34 to MRI of the brain. Risk factors, medical history, and functioning were assessed with  
35 questionnaires that the patients completed prior to their visit. Of the original 1309 patients  
36 comprising this cohort, 1232 successfully underwent MRI-measurement. For 994 of these  
37 patients, material for **MVEV** protein level measurement could be retrieved and had at least  
38 one **MVEV** protein level measurement. Between January 2006 and May 2009, all participants  
39 still alive (n = 1,238) were invited for follow-up measurements, including a second MRI of  
40 the brain. For 534 patients data on follow-up MRI as well as baseline **MVEV** protein levels  
41 were available. The SMART-MR study was approved by the ethics committee of the  
42 University Medical Center Utrecht, and written informed consent was obtained from all  
43 participants.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### *Magnetic resonance imaging protocol*

MR investigations were performed on a 1.5-Tesla whole-body system (Gyrosan ACS-NT, Philips Medical Systems, Best, The Netherlands). The protocol consisted of a transversal T1-weighted gradient-echo sequence (repetition time (TR)/echo time (TE): 235/2 ms; flip angle, 80°), a transversal T2-weighted turbo spin-echo sequence (TR/TE: 2200/11 ms and 2200/100 ms; turbo factor 12), a transversal T2-weighted fluid attenuating inverse recovery (FLAIR) sequence (TR/TE/inversion time (TI): 6000/100/2000 ms), and a transversal inversion recovery (IR) sequence (TR/TE/TI: 2900/22/410 ms) (field of view mm; matrix size; slice thickness, 4.0 mm; no gap; 38 slices).

### *Brain segmentation*

The T1-weighted gradient echo, IR sequence, and FLAIR sequence were used for brain segmentation with the probabilistic segmentation technique that has been described elsewhere<sup>27, 28</sup>. This segmentation program distinguishes cortical gray matter, normal appearing white matter, sulcal and ventricular cerebrospinal fluid (CSF) and lesions. The results of the segmentation analysis were visually checked for the presence of infarctions and adapted if necessary to make a distinction between white matter lesions and infarction volumes. Total brain volume was calculated by summing the volumes of gray and normal appearing white matter and, if present, the volumes of WML and infarcts. All volumes cranial to the foramen magnum were included. As a result, the total brain volume includes both hemispheres, brainstem, and cerebellum. Total intracranial volume (ICV) was calculated by summing the total brain volume and the volumes of the sulcal and ventricular CSF.

### *White matter lesions*

Periventricular WML were defined as WML adjacent to or within one centimeter of the lateral ventricles. Deep WML were defined as lesions located in deep white matter tracts or without adjoined periventricular lesions. If white matter hyperintensities on T2-weighted images were also hypointense on T1-weighted and FLAIR images, they were considered infarcts and therefore distinguished from WML.

### *Brain parameters*

Two brain parameters were used for analyses: WML, which was the sum of periventricular and deep WML in milliliters, expressed as percentage of ICV and brain parenchymal fraction (BPF), which was determined by calculating the total brain volume in milliliters as percentage

of ICV. By taking percentages of ICV instead of crude brain parameters, correction for differences in head size was applied.

#### *Extracellular Microvesicle measurements*

Complete measurement methods are described elsewhere<sup>7</sup>. **MVEV**s were isolated using ExoQuick™ (SBI) according to the manufacturer's protocol. Briefly, 150 µl EDTA plasma was centrifuged for 15 minutes at 3000 g. The supernatant was filtered over a 0.45 µm Spin-X filter (Corning), which was flushed with preheated PBS (37°C) and 38 µl ExoQuick™ solution was added to the filtrate. After vortexing, the sample was stored overnight at 4°C. The following day, the sample was centrifuged at 1500 g for 30 minutes at room temperature. After removing the supernatant, the pellet was lysed in 100 µl Roche Complete Lysis-M with protease inhibitors (EDTA free). Subsequently, the sample was filtered over a 0.22 µm Spin-X filter (Corning) and protein level was determined using a Pierce® BCA Protein Assay Kit (Pierce Biotechnology, Rockford, USA) before storing the sample at -80 °C. After thawing, the lysed sample was diluted 20x with Roche complete Lysis-M buffer. 50 µl of this diluted sample was analyzed in a multiplex immuno assay on levels of Cystatin C, Serpin G1, Serpin F2 & CD14, using a Bio-Rad Bioplex 200 system as described before<sup>29</sup>. Capture antibody, biotinylated detection antibody and antigen of all 4 proteins were purchased from R&D systems.

#### *Data analyses*

Central estimators and their variance measures were calculated for baseline characteristics. Multivariable linear regression was performed to assess the cross sectional relationship between **MVEV** protein level in pg/ml and WML in % or BPF in %. The fully adjusted model included age, gender, systolic blood pressure, smoking and type 2 diabetes, as these covariates are considered to be confounding factors in the suggested relationship between **EVmicrovesicle** protein levels and measured structural brain changes. To fulfill linear regression assumptions, WML volumes were naturally log-transformed as they showed skewed distributions. In order to directly compare strengths of associations, linear regressions were performed per standard deviation (SD) increase in **MVEV** protein level. Secondly, we assessed the prospective relationship between baseline **MVEV** protein levels and progression in brain parameters on MRI. This was done by relating baseline **MVEV** protein levels to follow-up WML or BPF. Besides adjustment for age, gender, systolic blood pressure, smoking and type 2 diabetes, these analyses were additionally adjusted for

1  
2  
3  
4  
5  
6  
7 baseline WML or BPF and follow-up time. Results are expressed as linear regression  
8 coefficients and 95% confidence intervals.  
9

## 10 11 12 **Results**

### 13 *Baseline characteristics*

14 Patient characteristics are displayed in Table 1. Seventy-nine percent of the initial patients  
15 were men and the mean age was 59±10 years. The majority of the patients had a (recent)  
16 medical history of CAD (58%), followed by CVD (26%), PAD (24%) and AAA (10%). After  
17 a mean interval time of 3.9±0.4 years, 534 patients underwent a second MRI of the brain. This  
18 follow-up cohort comprised 80% men and a mean baseline age of 58±9 years, which  
19 corresponded with a mean follow-up age of 62±9 years. For the baseline comparisons of the  
20 two groups, we refer to supplemental Table 1.  
21

### 22 *Cross-sectional association between MVEV protein levels and WML or BPF*

23 In the fully adjusted model, higher MVEV-Cystatin C and MVEV-CD14 were associated with  
24 more volume of WML. Regression coefficients per SD MVEV-protein were 0.10 (95%CI  
25 0.04-0.17) for MVEV-Cystatin C and 0.14 (95%CI 0.07–0.20) for MVEV-CD14 (Table 2).  
26

27 Also, higher MVEV-CD14 was associated with a statistically significantly lower BPF  
28 (regression coefficient per SD MVEV-CD14 -0.14 (95%CI -0.27–0.01)); (Table 3). SD  
29 increases of MVEV-Serpin G1 and MVEV-Serpin F2 were not related with WML or BPF at  
30 baseline.  
31

32 In general, adjustment for age and gender in model 2 altered the effect estimates substantially,  
33 whereas the impact that systolic blood pressure, smoking and type 2 diabetes had on the  
34 occurrence relation was relatively small. Tests for interaction by age and gender yielded non-  
35 significant results (data not shown).  
36  
37

### 38 *Prospective associations between MVEV protein levels and of WML or BPF*

39 In the fully adjusted model, higher MVEV-CD14 was associated with increase of WML  
40 volume (regression coefficient = 0.11 (95%CI 0.04-0.18)) as is displayed in Table 2. MVEV-  
41 Cystatin C, MVEV-Serpin G1 and MVEV-Serpin F2 were not related with increase of WML  
42 or BPF.  
43  
44  
45  
46  
47  
48  
49

## Discussion

In patients with various clinical manifestations of vascular disease, MVEV protein levels of Cystatin C and CD14 in plasma are associated with larger WML and more brain atrophy.

Furthermore, higher MVEV-CD 14 levels are associated with an increase in WML during 4 years of follow-up. This relation is independent of age, gender, systolic blood pressure, smoking and type 2 diabetes.

The role of Cystatin C, a cysteine protease inhibitor, in the process of degenerative disorders in the brain is unclear. In vitro and murine studies have shown that Cystatin C binds to amyloid- $\beta$  ( $\text{a}\beta$ ), resulting in inhibition of  $\text{a}\beta$  deposition<sup>30-32</sup>, the characteristic component of the neuritic plaques that identify patients with Alzheimer's disease. This protective role of Cystatin C was supported in a cohort study<sup>33</sup>, where lower levels of serum Cystatin C were associated with higher risk for future Alzheimer's disease in men. However, higher levels of serum Cystatin C have also been associated with cognitive decline<sup>34,35</sup> and with WML<sup>36</sup> in large population-based cohort studies. In WML, the Cystatin C expression is upregulated in astrocytes, presumably due to a self-defense response in the process of white matter degeneration<sup>37</sup>. Our results, based upon MVEV-Cystatin C, show similar results as increasing MVEV-Cystatin C is related to increased volume of WML. Cystatin C is secreted by all human tissues<sup>38</sup>, which presumably concomitantly shed Cystatin C<sup>+</sup> MVEVs in order to directly influence more distant processes.

CD14 is a cofactor for Toll-like receptor 4 (TLR4), which regulates NF $\kappa$ B expression, indicating a role for CD14 in inflammation<sup>39</sup>. CD14 is expressed on monocytes<sup>40</sup>, and it is therefore assumable that CD14<sup>+</sup> MVEVs originate from these monocytes. In our study, MVEV-CD14 levels were related to the volume and increase of WML. This indicates a MVEV-initiated inflammatory response in dealing with WML. These findings do not stand alone as several inflammatory biomarkers such as lipoprotein-associated phospholipase A2 (Lp-PLA2) and myeloperoxidase (MPO), have been associated with WML<sup>41</sup>. Although the effects of MVEV-CD14 on WML and BPF have not been assessed previously, soluble CD14 has been associated with cognitive impairment and brain atrophy in patients with HIV<sup>42</sup>.

Likewise, higher plasma levels of MVEV-CD14 were inversely related to BPF at baseline in our study.

MVEV-Serpin G1 (C1-inhibitor) and MVEV-Serpin F2 ( $\alpha$ 2-antiplasmin) were not associated with WML or BPF in our study, suggesting no substantial role of (inhibited) fibrinolysis in

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

the pathophysiology surrounding WML or brain atrophy. To our understanding this is the first report on these Serpins and their potential role in the etiology of WML and brain atrophy.

Whether and how MVEVs or MVEV protein levels might directly influence ischemic white matter lesions or brain volume is not known. Several mechanisms are proposed. We assume that MVEVs have blood-brain barrier penetrating properties, based upon recent data regarding exosomes<sup>24,25</sup>. It could also be that MVEVs interact with endothelial cells through receptor-mediated endocytosis. Once fused with these endothelial cells, EVmicrovesicle protein levels might activate inflammation cascade signaling, leading to vascular damage and subsequent arterial stiffness. It might also activate hemostasis cascade signaling leading to the formation of (micro)thrombi. Alternatively, through endocytosis by endothelial cells, MVEV protein levels might influence the structural integrity of the endothelial layer resulting in greater BBB permeability. Neurodegenerative disorders as Alzheimer disease<sup>43</sup> and multiple sclerosis<sup>44</sup> have been associated with BBB integrity loss. The mechanism behind this loss is unclear and perhaps EVmicrovesicles play a role within this process. Future work will have to test these hypotheses. If true causation between MVEV protein levels and brain changes would be the case, strategies on influencing MVEV protein levels should be developed.

Strengths of the present prospective cohort study include the relatively large sample size with various MVEV protein measurements and MRIs of the brain at baseline and 3.9 years follow up, which makes reversed causality less likely. Another strength of the study is the use of automated segmentation techniques to obtain brain parameters, which provides more precise and objective estimates than visual rating scales<sup>45</sup> and enables accurate measurement of small volume changes over time<sup>46</sup>.

Potential study limitations should also be considered. First, data of only 54% of the surviving cohort was used to measure change in WML or BPF. The patients who were physically able to undergo the follow-up MRI were most likely healthier than those who did not participate, which might have led to dilution of associations. Secondly, only 4 of the numerous proteins on the surface or within MVEVs were measured. It could well be that besides these vascular risk markers, various other MVEV proteins have their etiology in the structural brain changes.

Thirdly, we assume that plasma MVEVs which hold the proteins measured in the present study have the ability to cross the BBB in order to have their effects on the brain, influencing WML and BPF. Unfortunately no data is available whether these MVEVs are indeed present within the brain and it would be interesting to know if these MVEV proteins are present in cerebrospinal fluid and have a non-cerebral origin. If these MVEVs can truly pass the BBB and influence pathophysiological processes in the brain, it automatically gives rise to potential

therapeutical purposes analogous to exosomes, as these vesicles can deliver complex drugs directly into the brain, a key step in the treatment of brain diseases or brain changes<sup>47</sup>.

In conclusion, MVEV-Cystatin C and MVEV-CD14 levels are related with the volume of WML and with BPF on brain MRI. MVEV-CD14 levels are related with an increase in the total volume of WML during follow-up. Extracellular Microvesicle proteins levels may be causally related to brain changes in patients with clinically manifest vascular disease.

### Acknowledgments

We gratefully acknowledge the members of the SMART study group of UMC Utrecht: P.A. Doevendans, MD, PhD, Department of Cardiology; A. Algra, MD, PhD; Y. van der Graaf, MD, PhD; D.E. Grobbee, MD, PhD, G.E.H.M. Rutten, MD, PhD, Julius Center for Health Sciences and Primary Care; L.J. Kappelle, MD, PhD, Department of Neurology; W.P.T.M. Mali, MD, PhD, Department of Radiology; F.L. Moll, MD, PhD, Department of Vascular Surgery; F.L.J. Visseren, MD, PhD, Department of Vascular Medicine.

We thank, A.H. Schoneveld, L. Collee and S. van der Weg for the measurement of the plasma extracellular microvesicle proteins.

### Funding sources

This work was financially supported by the UMC Utrecht Vascular Prevention Project.

### Disclosures

The authors declare no conflict of interest.

### References

1. Geerlings MI, Appelman AP, Vincken KL, Algra A, Witkamp TD, Mali WP, van der Graaf Y; SMART Study Group. Brain volumes and cerebrovascular lesions on MRI in patients with atherosclerotic disease. The SMART-MR study. *Atherosclerosis*. 2010; 210:130–136.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

2. Breteler MM, van Swieten JC, Bots ML, Grobbee DE, Claus JJ, van den Hout JH, van Harskamp F, Tanghe HL, de Jong PT, van Gijn J, Hofman A. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. *Neurology*. 1994;44:1246-52.

3. Vinkers DJ, Stek ML, van der Mast RC, de Craen AJ, Le Cessie S, Jolles J, Westendorp RG, Gussekloo J. Generalized atherosclerosis, cognitive decline, and depressive symptoms in old age. *Neurology*. 2005;65:107-12.

4. Breteler MM, Claus JJ, Grobbee DE, Hofman A. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. *BMJ*. 1994;308:1604-8.

5. Nash DT, Fillit H. Cardiovascular disease risk factors and cognitive impairment. *Am J Cardiol*. 2006;97:1262-5.

6. Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia: how to move forward? *Neurology*. 2009;72:368-74.

7. Kanhai DA, Visseren FL, van der Graaf Y, Schoneveld AH, Catanzariti LM, Timmers L, Kappelle LJ, Uiterwaal CS, Lim SK, Sze SK, Pasterkamp G, de Kleijn DP. Microvesicle protein levels are associated with increased risk for future vascular events and mortality in patients with clinically manifest vascular disease. *Int. J. Cardiol.* - 2013;3:168:2358-632013. ~~In press.~~

8. Sinning JM, Losch J, Walenta K, Böhm M, Nickenig G, Werner N. Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. *Eur Heart J*. 2011;32:2034-2041.

9. Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. *Trends Cell Biol*. 2009;19:43-51.

Formatted: English (U.S.)



- 1  
2  
3  
4  
5  
6  
7 10. van der Vlist EJ, Nolte-'t Hoen EN, Stoorvogel W, Arkesteijn GJ, Wauben MH.  
8 Fluorescent labeling of nano-sized vesicles released by cells and subsequent quantitative and  
9 qualitative analysis by high-resolution flow cytometry. *Nat Protoc.* 2012;7:1311-26.  
10  
11  
12 11. Jy W, Horstman LL, Jimenez JJ, Ahn YS, Biró E, Nieuwland R, Sturk A, Dignat-George  
13 F, Sabatier F, Camoin-Jau L, Sampol J, Hugel B, Zobairi F, Freyssinet JM, Nomura S, Shet  
14 AS, Key NS, Hebbel RP. Measuring circulating cell-derived microparticles. *J Thromb*  
15 *Haemost.* 2004;2:1842–1851.  
16  
17  
18 12. Morel O, Morel N, Hugel B, Jesel L, Vinzio S, Goichot B, Bakouboula B, Grunebaum L,  
19 Freyssinet JM, Toti F. The significance of circulating microparticles in physiology,  
20 inflammatory and thrombotic diseases. *Rev Med Interne.* 2005;26:791–801.  
21  
22  
23 13. Martinez MC, Tual-Chalot S, Leonetti D, Andriantsitohaina R. Microparticles: targets and  
24 tools in cardiovascular disease. *Trends Pharmacol Sci.* 2011;32:659-65.  
25  
26  
27 14. Wang JG, Williams JC, Davis BK, Jacobson K, Doerschuk CM, Ting JP, Mackman N.  
28 Monocytic microparticles activate endothelial cells in an IL-1 $\beta$ -dependent manner. *Blood.*  
29 2011;118:2366-74.  
30  
31  
32 15. Owens AP 3rd, Mackman N. Microparticles in hemostasis and thrombosis. *Circ Res.*  
33 2011;108:1284-97.  
34  
35  
36 16. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in  
37 hemostasis and thrombosis. *Arterioscler Thromb Vasc Biol.* 2007;27:1687-93.  
38  
39  
40 17. Leroyer AS, Isobe H, Lesèche G, Castier Y, Wassef M, Mallat Z, Binder BR, Tedgui A,  
41 Boulanger CM. Cellular origins and thrombogenic activity of microparticles isolated from  
42 human atherosclerotic plaques. *J Am Coll Cardiol.* 2007;49:772-7.  
43  
44  
45 18. Fauré J, Lachenal G, Court M, Hirrlinger J, Chatellard-Causse C, Blot B, Grange J,  
46 Schoehn G, Goldberg Y, Boyer V, Kirchhoff F, Raposo G, Garin J, Sadoul R. Exosomes are  
47 released by cultured cortical neurones. *Mol Cell Neurosci.* 2006;31:642-8.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

19. Amabile N, Guérin AP, Leroyer A, Mallat Z, Nguyen C, Boddaert J, London GM, Tedgui A, Boulanger CM. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. *J Am Soc Nephrol*. 2005;16:3381-8.

20. O'Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. *Hypertension*. 2005;46:200–204.

21. Ohmine T, Miwa Y, Yao H, Yuzuriha T, Takashima Y, Uchino A, Takahashi-Yanaga F, Morimoto S, Maehara Y, Sasaguri T. Association between arterial stiffness and cerebral white matter lesions in community-dwelling elderly subjects. *Hypertens Res*. 2008;31:75– 81.

22. Kuo HK, Chen CY, Liu HM, Yen CJ, Chang KJ, Chang CC, Yu YH, Lin LY, Hwang JJ. Metabolic risks, white matter hyperintensities, and arterial stiffness in high-functioning healthy adults. *Int J Cardiol*. 2010;143:184–191.

23. Jimenez JJ, Jy W, Mauro LM, Horstman LL, Ahn YS. Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease. *Br J Haematol*. 2001;112:81-90.

24. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhil S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. *Nat Biotechnol*. 2011;29:341-5.

25. Graner MW, Alzate O, Dechkovskaia AM, Keene JD, Sampson JH, Mitchell DA, Bigner DD. Proteomic and immunologic analyses of brain tumor exosomes. *FASEB J*. 2009;23:1541-57.

26. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifestations of ARterial disease (SMART) study: rationale and design. *Eur J Epidemiol*. 1999;15:773-781.

27. Anbeek P, Vincken KL, van Osch MJ, Bisschops RH, van der Grond J. Probabilistic segmentation of white matter lesions in MR imaging. *Neuroimage*. 2004;21:1037-44.

- 1  
2  
3  
4  
5  
6  
7 28. Anbeek P, Vincken KL, van Bochove GS, van Osch MJ, van der Grond J. Probabilistic  
8 segmentation of brain tissue in MR imaging. *Neuroimage*. 2005;27:795-804.  
9
- 10  
11 29. Schipper HS, de Jager W, van Dijk ME, Meerding J, Zelissen PM, Adan RA, Prakken BJ,  
12 Kalkhoven E. A multiplex immunoassay for human adipokine profiling. *Clin Chem*.  
13 2010;56:1320-8.  
14
- 15  
16  
17 30. Sastre M, Calero M, Pawlik M, Mathews PM, Kumar A, Danilov V, Schmidt SD, Nixon  
18 RA, Frangione B, Levy E. Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro  
19 amyloid fibril formation. *Neurobiol Aging*. 2004;25:1033-43.  
20
- 21  
22  
23 31. Kaeser SA, Herzig MC, Coomaraswamy J, Kilger E, Selenica ML, Winkler DT,  
24 Staufenbiel M, Levy E, Grubb A, Jucker M. Cystatin C modulates cerebral beta-amyloidosis.  
25 *Nat Genet*. 2007;39:1437-9.  
26
- 27  
28  
29 32. Mi W, Pawlik M, Sastre M, Jung SS, Radvinsky DS, Klein AM, Sommer J, Schmidt SD,  
30 Nixon RA, Mathews PM, Levy E. Cystatin C inhibits amyloid-beta deposition in Alzheimer's  
31 disease mouse models. *Nat Genet*. 2007 ;39:1440-2.  
32
- 33  
34  
35 33. Sundelöf J, Arnlöv J, Ingelsson E, Sundström J, Basu S, Zethelius B, Larsson A, Irizarry  
36 MC, Giedraitis V, Rönnekaa E, Degerman-Gunnarsson M, Hyman BT, Basun H, Kilander L,  
37 Lannfelt L. Serum cystatin C and the risk of Alzheimer disease in elderly men. *Neurology*.  
38 2008;71:1072-9.  
39
- 40  
41  
42 34. Yaffe K, Lindquist K, Shlipak MG, Simonsick E, Fried L, Rosano C, Satterfield S,  
43 Atkinson H, Windham BG, Kurella-Tamura M. Cystatin C as a marker of cognitive function  
44 in elders: findings from the health ABC study. *Ann Neurol*. 2008;63:798-802.  
45
- 46  
47  
48 35. Rajagopalan P, Refsum H, Hua X, Toga AW, Jack CR Jr, Weiner MW, Thompson PM;  
49 Alzheimer's Disease Neuroimaging Initiative. Mapping creatinine- and cystatin C-related  
50 white matter brain deficits in the elderly. *Neurobiol Aging*. 2012; [Epub ahead of print]  
51  
52  
53  
54  
55

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

36. Wada M, Nagasawa H, Kawanami T, Kurita K, Daimon M, Kubota I, Kayama T, Kato T. Cystatin C as an index of cerebral small vessel disease: results of a cross-sectional study in community-based Japanese elderly. *Eur J Neurol*. 2010;17:383-90.

37. Umegae N, Nagai A, Terashima M, Watanabe T, Shimode K, Kobayashi S, Masuda J, Kim SU, Yamaguchi S. Cystatin C expression in ischemic white matter lesions. *Acta Neurol Scand*. 2008;118:60-7.

38. Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C. *Crit Rev Clin Lab Sci*. 2004;41:467-550.

39. Jiang Q, Akashi S, Miyake K, Petty HR. Lipopolysaccharide induces physical proximity between CD14 and toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-kappa B. *J Immunol*. 2000;165:3541-4.

40. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, Leenen PJ, Liu YJ, MacPherson G, Randolph GJ, Scherberich J, Schmitz J, Shortman K, Sozzani S, Strobl H, Zembala M, Austyn JM, Lutz MB. Nomenclature of monocytes and dendritic cells in blood. *Blood*. 2010;116:e74-80.

41. Wright CB, Moon Y, Paik MC, Brown TR, Rabbani L, Yoshita M, DeCarli C, Sacco R, Elkind MS. Inflammatory biomarkers of vascular risk as correlates of leukoariosis. *Stroke*. 2009;40:3466-71.

42. Ryan LA, Zheng J, Brester M, Bohac D, Hahn F, Anderson J, Ratanasuwan W, Gendelman HE, Swindells S. Plasma levels of soluble CD14 and tumor necrosis factor-alpha type II receptor correlate with cognitive dysfunction during human immunodeficiency virus type 1 infection. *J Infect Dis*. 2001;184:699-706.

43. Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, Vitek MP, Hovanesian V, Stopa EG. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. *Neurobiol Aging*. 2007;28:977-86.

- 1  
2  
3  
4  
5  
6  
7 44. Waubant E. Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis.  
8 *Dis Markers*. 2006;22:235-44.  
9  
10  
11 45. Yoshita M, Fletcher E, DeCarli C. Current concepts of analysis of cerebral white matter  
12 hyperintensities on magnetic resonance imaging. *Top Magn Reson Imaging*. 2005;16:399-  
13 407.  
14  
15  
16  
17 46. van den Heuvel DM, ten Dam VH, de Craen AJ, Admiraal-Behloul F, van Es AC, Palm  
18 WM, Spilt A, Bollen EL, Blauw GJ, Launer L, Westendorp RG, van Buchem MA; PROSPER  
19 Study Group. Measuring longitudinal white matter changes: comparison of a visual rating  
20 scale with a volumetric measurement. *Am J Neuroradiol*. 2006;27:875-8.  
21  
22  
23  
24 47. Wood MJ, O'Loughlin AJ, Samira L. Exosomes and the blood-brain barrier: implications  
25 for neurological diseases. *Ther Deliv*. 2011;2:1095-9.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60Table 1: **Baseline** patient characteristics

	Baseline cohort N = 994	Follow-up patients N = 534	Non-FU patients N = 460
Age (years)*	59 ± 10	58 ± 9	60 ± 11
Male gender, n (%)	784 (79)	426 (80)	358 (78)
Body mass index (kg/m <sup>2</sup> )*	26.9 ± 3.8	26.9 ± 3.6	26.8 ± 4.1
Waist circumference (cm)*	95 ± 11	95 ± 11	96 ± 12
Blood pressure (mmHg)*			
Systolic	144 ± 22	142 ± 20	145 ± 23
Diastolic	83 ± 12	82 ± 11	83 ± 12
LDL-cholesterol (mmol/L)*	2.8 ± 0.93	2.8 ± 0.90	2.9 ± 0.97
HDL-cholesterol (mmol/L)*	1.30 ± 0.38	1.31 ± 0.38	1.28 ± 0.37
Triglycerides (mmol/L) <sup>‡</sup>	1.47 (1.09 – 2.07)	1.41 (1.05 – 2.07)	1.47 (1.09-2.07)
Glucose (mmol/L)*	6.3 ± 1.9	6.2 ± 1.8	6.4 ± 1.9
HsCRP (mmol/L) <sup>‡</sup>	1.8 (0.9 – 3.8)	1.6 (0.8 – 3.5)	1.8 (0.9 - 3.8)
eGFR (ml/min/1.73 m <sup>2</sup> )*	77.7 ± 17.9	79.7 ± 17.1	75.4 ± 18.6
Homocysteine (µmol/L)*	14.0 ± 6.0	13.5 ± 4.9	14.6 ± 7.0
Prevalent type 2 diabetes, n (%)	156 (16)	71 (13)	85 (19)
Metabolic syndrome, n (%) <sup>†</sup>	369 (37)	184 (35)	185 (40)
Smoking, n (%)			
Never	170 (17)	100 (18)	70 (15)
Ever	454 (46)	257 (48)	197 (43)
Current	370 (37)	177 (33)	193 (42)
Packyears smoking*	23.0 ± 20.5	23.0 ± 20.1	23.1 ± 21.0
History of vascular disease, n (%)			
Cerebrovascular disease	261 (26)	144 (27)	117 (25)
Coronary artery disease	580 (58)	325 (61)	255 (55)
Peripheral artery disease	241 (24)	108 (20)	133 (29)
Aneurysm of the abdominal aorta	99(10)	37 (7)	62 (14)
Medication, n (%)			
Platelet-aggregation inhibitors	740 (74)	407 (76)	333 (72)
Blood pressure-lowering agents	702 (71)	382 (72)	320 (70)
Lipid-lowering agents	682 (69)	388 (73)	294 (64)
Oral anticoagulants	80 (8)	37 (7)	43 (9)
<b>White matter lesions (log%)<sup>*</sup></b>	<b>-2.1 (1.1)</b>	<b>-2.3 (1.1)</b>	<b>-1.9 (1.1)</b>
<b>Brain parenchymal fraction (%)<sup>*</sup></b>	<b>79 (3)</b>	<b>79 (3)</b>	<b>79 (3)</b>

Values are expressed as: \*Mean ± standard deviation, <sup>‡</sup>Median (interquartile range).

<sup>†</sup>Defined according to the National Cholesterol Education Program ATP III-revised guidelines.

Formatted: Superscript

Formatted: Centered

Formatted: Superscript

Formatted: Centered

**Table 2: Extracellular Microvesicle protein levels and white matter lesions (WML)**

	Model	WML	
		WML at baseline n=994	WML at follow-up* n= 534
<b>MVEV</b> -Cystatin C (pg/μg) Mean 10.6 SD 5.3	I	<b>0.27 (0.20 – 0.34)</b>	0.06 (-0.02 – 0.13)
	II	<b>0.10 (0.04 – 0.17)</b>	0.01 (-0.06 – 0.08)
	III	<b>0.10 (0.04 – 0.17)</b>	0.01 (-0.06 – 0.08)
<b>MVEV</b> -Serpin G1 (pg/μg) Mean 142.2 SD 85.6	I	-0.03 (-0.10 – 0.05)	0.02 (-0.05 – 0.08)
	II	-0.02 (-0.08 – 0.04)	0.02 (-0.04 – 0.08)
	III	-0.03 (-0.08 – 0.05)	0.03 (-0.03 – 0.09)
<b>MVEV</b> -Serpin F2 (pg/μg) Mean 43.3 SD 30.4	I	0.01 (-0.066 – 0.08)	-0.01 (-0.08 – 0.05)
	II	0.03 (-0.034 – 0.09)	0.01 (-0.06 – 0.07)
	III	0.03 (-0.035 – 0.09)	0.01 (-0.05 – 0.07)
<b>MVEV</b> -CD 14 (pg/μg) Mean 12.2 SD 3.9	I	<b>0.23 (0.16 – 0.30)</b>	<b>0.12 (0.04 – 0.18)</b>
	II	<b>0.14 (0.08 – 0.20)</b>	<b>0.10 (0.03 – 0.17)</b>
	III	<b>0.14 (0.07 – 0.20)</b>	<b>0.11 (0.04 – 0.18)</b>

Regression coefficients: increase in WML (log%) per 1SD increase in **MVEV** protein level (pg/ml)

Model I: Univariable model

Model II: Adjustment for age and gender

Model III: Model II with additional adjustment for systolic blood pressure, packyears smoking and prevalent type 2 diabetes mellitus

\*Models include additional adjustment for baseline WML and follow-up time

**Table 3: Extracellular Microvesicle protein levels and Brain Parenchymal Fraction (BPF)**

	Model	BPF	
		BPF at baseline n=994	BPF at follow-up* n= 534
<b>MVEV</b> -Cystatin C (pg/μg) <i>Mean 10.6</i> <i>SD 5.3</i>	I	<b>-0.69 (-0.86 - -0.51)</b>	<b>-0.15 (-0.26 - -0.04)</b>
	II	-0.12 (-0.26 - 0.02)	-0.06 (-0.16 - 0.04)
	III	-0.11 (-0.24 - 0.03)	-0.05 (-0.16 - 0.05)
<b>MVEV</b> -Serpin G1 (pg/μg) <i>Mean 142.2</i> <i>SD 85.6</i>	I	-0.00 (-0.18 - 0.17)	0.04 (-0.05 - 0.14)
	II	0.01 (-0.12 - 0.14)	0.02 (-0.06 - 0.11)
	III	0.10 (-0.12 - 0.14)	0.03 (-0.06 - 0.11)
<b>MVEV</b> -Serpin F2 (pg/μg) <i>Mean 43.3</i> <i>SD 30.4</i>	I	0.05 (-0.12 - 0.23)	0.06 (-0.04 - 0.16)
	II	-0.10 (-0.23 - 0.03)	-0.01 (-0.10 - 0.08)
	III	-0.06 (-0.19 - 0.07)	0.01 (-0.09 - 0.10)
<b>MVEV</b> -CD 14 (pg/μg) <i>Mean 12.2</i> <i>SD 3.9</i>	I	<b>-0.45 (-0.62 - -0.28)</b>	-0.06 (-0.17 - 0.05)
	II	<b>-0.19 (-0.32 - -0.06)</b>	-0.05 (-0.15 - 0.05)
	III	<b>-0.14 (-0.27 - -0.01)</b>	-0.03 (-0.13 - 0.07)

Regression coefficients: increase in BPF (%) per 1SD increase in **MVEV** protein level (pg/ml)

Model I: Univariable model

Model II: Adjustment for age and gender

Model III: Model II with additional adjustment for systolic blood pressure, packyears smoking and prevalent type 2 diabetes mellitus

\*Models include additional adjustment for baseline WML and follow-up time



**Suppl. Table 1.** Baseline characteristics and mean difference between follow-up and non-follow up patients

	<b>Follow-up patients N = 534</b>	<b>Non-FU patients N = 460</b>	<b>Mean difference (95% CI)</b>
Age (years)*	58 ± 9	60 ± 11	2.4 (1.2–3.6)
Male gender, n (%)	426 (80)	358 (78)	-0.02 (-0.07–0.03)
Body mass index (kg/m <sup>2</sup> )*	26.9 ± 3.6	26.8 ± 4.1	0.2 (-0.6–0.4)
Waist circumference (cm)*	95 ± 11	96 ± 12	0.7 (-0.7–2.0)
Blood pressure (mmHg)*			
Systolic	142 ± 20	145 ± 23	1.4 (1.3–6.8)
Diastolic	82 ± 11	83 ± 12	1.8 (0.4–3.2)
LDL-cholesterol (mmol/L)*	2.8 ± 0.90	2.9 ± 0.97	0.06 (0.05–0.28)
HDL-cholesterol (mmol/L)*	1.31 ± 0.38	1.28 ± 0.37	0.03 (-0.07–0.02)
Triglycerides (mmol/L) <sup>‡</sup>	1.41 (1.05 – 2.07)	1.47 (1.09-2.07)	0.07 (0.03–0.30)
Glucose (mmol/L)*	6.2 ± 1.8	6.4 ± 1.9	0.12 (-0.02–0.45)
HsCRP (mmol/L) <sup>‡</sup>	1.6 (0.8 – 3.5)	1.8 (0.9 - 3.8)	0.60 (-0.80–1.57)
eGFR (ml/min/1.73 m <sup>2</sup> )*	79.7 ± 17.1	75.4 ± 18.6	1.13 (-6.43–2.00)
Homocysteine (µmol/L)*	13.5 ± 4.9	14.6 ± 7.0	0.38 (0.38–1.88)
Prevalent type 2 diabetes, n (%)	71 (13)	85 (19)	-0.05 (-0.10–0.00)
Metabolic syndrome, n (%) <sup>†</sup>	184 (35)	185 (40)	-0.06 (-0.12–0.01)
Smoking, n (%)			
Never	100 (18)	70 (15)	0.04 (-0.01–0.08)
Ever	257 (48)	197 (43)	0.05 (-0.01–0.12)
Current	177 (33)	193 (42)	-0.09 (-0.15–0.03)
Packyears smoking*	23.0 ± 20.1	23.1 ± 21.0	1.31 (-2.51–2.62)
History of vascular disease, n (%)			
Cerebrovascular disease	144 (27)	117 (25)	0.02 (-0.04–0.07)
Coronary artery disease	325 (61)	255 (55)	0.05 (-0.01–0.12)
Peripheral artery disease	108 (20)	133 (29)	-0.09 (-0.14–0.03)
Aneurysm of the abdominal aorta	37 (7)	62 (14)	-0.07 (-0.10–0.03)
Medication, n (%)			
Platelet-aggregation inhibitors	407 (76)	333 (72)	0.04 (-0.02–0.09)
Blood pressure-lowering agents	382 (72)	320 (70)	0.02 9-0.04–0.08)
Lipid-lowering agents	388 (73)	294 (64)	0.09 (0.03–0.14)
Oral anticoagulants	37 (7)	43 (9)	-0.02 (-0.06–0.01)

Values are expressed as: \*Mean ± standard deviation, <sup>‡</sup>Median (interquartile range).

<sup>†</sup>Defined according to the National Cholesterol Education Program ATPIII-revised guidelines.

## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract → Title/Abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found → Abstract
<b>Introduction</b>		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported → Introduction page 3
Objectives	3	State specific objectives, including any prespecified hypotheses → Introduction page 4
<b>Methods</b>		
Study design	4	Present key elements of study design early in the paper → Methods page 4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection → Methods page 4-5
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up → Methods page 4-5 <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable → Methods page 5-6
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group → Methods page 5-6
Bias	9	Describe any efforts to address potential sources of bias → Methods page 6-7
Study size	10	Explain how the study size was arrived at → Methods page 4-5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why → Methods Page 6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding → Methods page 7 (b) Describe any methods used to examine subgroups and interactions → Methods page 7 (c) Explain how missing data were addressed → Methods page 4 (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed → Methods page 5 <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

sampling strategy

---

(e) Describe any sensitivity analyses

Continued on next page

For peer review only

**Results**

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed → <a href="#">Methods page 4, Results: Table 1</a> (b) Give reasons for non-participation at each stage → <a href="#">Discussion</a> (c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders → <a href="#">Results: Table 1; page 7</a> (b) Indicate number of participants with missing data for each variable of interest → <a href="#">N.A</a> (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time → <a href="#">Results: Table 2; page 7-8</a> <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included → <a href="#">Results: Table 2, page 7-8</a> (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses → <a href="#">Results page 7; suppl Table 1</a>

**Discussion**

Key results	18	Summarise key results with reference to study objectives → <a href="#">Discussion page 8</a>
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias → <a href="#">Discussion page 9</a>
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence → <a href="#">Discussion page 10</a>
Generalisability	21	Discuss the generalisability (external validity) of the study results → <a href="#">Discussion page 10</a>

**Other information**

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based → <a href="#">Funding sources page 10</a>
---------	----	---

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).